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Chronic inflammatory enteropathies (CIE) occur frequently and are an important group of con-
ditions in dogs. Similar to people with inflammatory bowel disease (IBD), dogs with CIE typ-
ically present with chronic gastrointestinal signs, including diarrhea, vomiting, weight loss, and 
sometimes abdominal pain. Distinguishing small bowel diarrhea (characterized by an increased 
fecal volume, melena, weight loss, and sometimes steatorrhea [HALL AND GERMAN 2010]), 
from large bowel diarrhea (mucus in the feces, tenesmus, and fecal urgency [ALLENSPACH 
2010]) can aid in the clinical decision-making process (e.g., planning the optimal diagnostic 
steps). In a dog suspected of vomiting, it is also important to differentiate vomiting from 
regurgitation because the differential diagnoses for those two clinical problems differ 
profoundly. 
Gastrointestinal signs in dogs can be acute, chronic, or acute-on-chronic in nature. Infections 
(viral, parasitic, or bacterial), dietary indiscretion, and toxin ingestion are the most common 
causes of acute gastrointestinal signs in canine patients (ALLENSPACH and GASCHEN 
2011). Chronic enteropathies are characterized by the presence of persistent or intermittent clin-
ical signs for at least 3 weeks (WASHABAU ET AL. 2010, ALLENSPACH 2016, DAN-
DRIEUX 2016). Beyond the common signs of an acute gastroenteropathy (vomiting, diarrhea, 
and abdominal pain), dogs with CIE may show borborygmus, flatulence, hyporexia, lip-smack-
ing, and/or licking fits. A definitive diagnosis requires laboratory and fecal examinations as 
well as diagnostic imaging to rule out infectious or mechanical-obstructive gastrointestinal or 
extra-gastrointestinal causes (ERDMANN and HEILMANN 2017). Histopathological evalua-
tion of gastrointestinal tissue biopsies is then needed to document inflammation, rule out a ne-
oplastic condition, and characterize the inflammatory infiltrate. Dogs with CIE are further sub-
classified based on the response to treatment as either food-responsive enteropathy (FRE; if the 
clinical signs significantly improve or resolve following an elimination diet trial) or idiopathic 
steroid- and/or immunosuppressant-responsive (or -refractory) enteropathy (SRE/IRE; if treat-
ment with a corticosteroid [e.g., prednisolone or budesonide] and/or other immunosuppressant 
medication [e.g., cyclosporine, azathioprine, or chlorambucil] is needed) (ALLENSPACH 
2016, DANDRIEUX 2016). Protein-losing enteropathy is characterized by an intestinal protein 
loss due to primary or secondary lymphangiectasia, which generally carries a worse prognosis, 
and affected dogs can develop hypoalbuminemia. 
Presenting a primary (idiopathic) inflammatory condition, IRE/SRE is a diagnosis of exclusion. 
The pathogenesis of this disease entity appears to be complex, and current knowledge suggests 





immune system: the innate immune response (also called natural or non-specific immunity) and 
the acquired immune response (also referred to as adaptive or specific immunity). An innate 
immune system exists in virtually all living creatures, even simple single-celled organisms such 
as bacteria have enzymatic systems that protect against viral infections. In higher-order 
organisms, the innate immune system can detect various damage-associated molecular pattern 
(DAMP) molecules released from cells (also called alarmins) as well as signals associated with 
the presence of pathogens called pathogen-associated molecular pattern (PAMP) molecules, 
thus allowing for the identification of damaged or infected cells (LOZANO SOTO 2012). The 
acquired immune system has equipped vertebrates, including humans and dogs, with more 
sophisticated defense mechanisms interconnected with the innate immune system in a dynamic 
but more longitudinal fashion. With lymphocytes as the functional basis of the adaptive immune 
system, this immune system arm can adapt to recognize specific pathogens more efficiently 
(immune memory) and provides the basis for immune tolerance towards certain antigens 
encountered at mucosal surfaces (BERKOW 2008, LOZANO SOTO 2017). 
Pattern-recognition receptors (PRRs) belong to the innate immune system and can recognize 
DAMP and PAMP molecules (HEILMANN and ALLENSPACH 2017). One of these innate 
immune receptors is the receptor for advanced glycation end products (RAGE), which has a 
central role in the pathogenesis of chronic inflammatory diseases in humans (BIERHAUS et al. 
2005). RAGE as a non-specific PRR binds to several DAMP molecules, including S100/cal-
granulin proteins S100A8/A9 and S100A12 (BIERHAUS et al. 2005, HEILMANN and 
ALLENSPACH 2017). Transmembrane (full-length) RAGE consists of 5 different domains, of 
which the cytoplasmic tail presents the distal portion of the receptor and can activate the 
intracellular inflammatory cascade (HEILMANN and ALLENSPACH 2017). Soluble RAGE 
(sRAGE) is a decoy receptor that can bind circulating ligands of RAGE but lacks the 
cytoplasmic part to induce pro-inflammatory post-receptor signaling. Because sRAGE 
competes with transmembrane (full-length) RAGE for ligand (e.g., DAMP) binding, the 
intracellular inflammatory cascade is not activated (HEILMANN and ALLENSPACH 2017), 
potentially leading to an abrogation of inflammation. 
There are 24 variants of RAGE in dogs (STERENCZAK et al. 2009). This PRR has been 
evaluated in canine patients with malignant neoplasms (histiocytic sarcoma, lymphoma) 
(STERENCZAK et al. 2010, STERENCZAK et al. 2011) but has not been studied or reported 
in dogs with chronic gastrointestinal inflammation (i.e., CIE). Decreases in serum sRAGE 
concentrations were detected in canine CIE. However, the RAGE/sRAGE axis and its role in 
the inflammatory response have not been further investigated in dogs with this condition.




2. REVIEW OF LITERATURE 
2.1 Functional Anatomy and Physiology of the Intestines 
2.1.1 Anatomy of the Intestines 
The intestine (Latin intestinum, Greek ἔντερον), or gut, is the longest part of the digestive tract 
of higher multicellular animals, including dogs. Anatomically, the intestine is divided into two 
main portions: the small intestine and the large intestine or colon (HELANDER 2014). 
The small intestine (intestinum tenue) is the section of the digestive tract where most of the 
hydrolytic cleavage of the ingesta by endogenous pancreatic and intestinal brush border 
enzymes occurs (HELANDER 2014). The small intestine constitutes of three segments: the 
duodenum, jejunum, and ileum. The duodenum emerges right from the gastric pylorus. The 
proximal portion of the duodenum (pars cranialis duodeni) directly faces the intestinal surface 
of the liver, which it connects to by the hepatoduodenal ligament. The duodenum then follows 
a caudal direction with the cranial duodenal flexure (flexura duodenalis cranialis). The subse-
quent pars descendens duodeni has attached a comparatively long mesentery in the dog, in 
which the right lobe of the pancreas is embedded (SCHUMMER 1987). The pars ascendens 
duodeni is attached to a shorter mesentery and is located between the cecum and descending 
colon. The pars ascendens duodeni and colon descendens are connected through the plica 
duodenocolica, which continues to the rectum. With the flexura duodenojejunalis, the 
ascending duodenum enters into the jejunum, the longest segment of the small intestine 
comprised of six to eight jejunal loops located between the stomach and pelvic entrance 
(SCHUMMER 1987). The ileum, as the last segment of the small intestine, connects to the 
colon. It opens into the large intestine, between the cecum and ascending colon, with the ostium 
ileale (WISSDORF 1976). 
The intestinal wall has a similar structure in all three small intestine segments and comprises 
the mucosa, submucosa, muscularis propria, subserosa, and serosa (Fig. 1). Blood is supplied 
to the small intestine from the arteria coeliaca and arteria mesenterica cranialis, and nutrient-
rich blood from the intestine is transported to the liver via the portal vein (WISSDORF 1976). 
The lymphatic drainage system of the small intestine originates from chylous capillaries of the 
small intestinal villi (Fig. 1). Regional lymph nodes of the small intestine include the jejunal, 
pancreaticoduodenal, and colic lymph nodes. 
 
 




Figure 1: Detailed cross-section showing the organization of blood and lymph vessels of 





The large intestine (intestinum crassum) is essentially the main segment to absorb water and 
electrolytes from the intestinal lumen. The large intestine consists of the cecum, colon, and 
rectum. The cecum in dogs has a corkscrew-like appearance and measures between 40 and 150 
mm; the length doubles when folds elapse. Through the mesocecum of the mesenteric root and 
the plica ileocecalis, the location of the cecum remains constant, mainly within the right 
quadrant of the abdomen (SCHUMMER 1987). The colon describes a U-shaped loop that rises 
to the right, then crosses over to the left, cranial to the mesenteric root, and then descends to 
the pelvic entrance. Accordingly, the colon is comprised of the colon ascendens, colon 
transversum, and colon descendens. The rectum begins at the level of the 7th lumbar vertebra. 
Within the peritoneal cavity, before entering the pelvic canal, the rectum is attached to a short 
mesentery, the mesorectum (SCHUMMER 1987). 
The histomorphology of the large intestinal wall follows in principle that of the small intestine, 
with the exception that the large intestinal mucosa lacks any villi (Fig. 2). The lymphatic 










Figure 2: Schematic of the large intestinal wall. 
 
 
2.1.2 Gastrointestinal Physiology 
Several aspects of gastrointestinal function are important for the physiologic mechanisms of 
the gastrointestinal tract and to understand and address gastrointestinal pathologies. These in-
clude gastrointestinal motility, secretion, digestion and absorption, and mucosal barrier func-
tion. 
Following the ingestion of a meal, the stomach contents are released into the small intestine by 
rhythmic contractions of the pyloric muscles, which occur every 15–20 seconds. In the small 
intestine, the ingesta are gradually mixed with intestinal secretions and are transported aborally 
by periodic segmentation and pendulous contractions of the intestinal wall. The chyme then 
reaches the large intestine approximately 60–90 minutes after passing into the duodenum 
(ZENTEK 2016). During passage through the small intestine, the crucial steps of digestion 
occur. These include the breakdown of nutrient complexes into smaller, soluble substances and 
the absorption of these small molecules through the intestinal wall and into the circulation. At 
the distalmost portion of the ileum, the digestion of proteins and fats is nearly complete with 
highly digestible rations, but not with complex rations that are more difficult to digest 
(ZENTEK 2016). 
Pancreatic secretions are essential in gastrointestinal physiology. The secretion of electrolytes 
and water occurs in the acinar cells of the pancreatic acini and the duct cells of the pancreatic 




duct system, although the duct cells generally play a dominant role (ENGELHARDT and 
BREVES 2000). Digestive enzymes such as peptidases, nucleases, amylases, and lipases are 
secreted by the acinar cells of the pancreas via exocytosis, partly as inactive pro-enzymes and 
partly as activated enzymes (ENGELHARDT and BREVES 2000). The inactive pro-enzyme 
forms of pancreatic enzymes are activated in the small intestine. Enteropeptidase (also referred 
to as enterokinase) is an intestinal brush border enzyme that activates trypsinogen to trypsin by 
enzymatic removal of a hexapeptide. Other pancreatic pro-enzymes secreted into the small in-
testinal lumen are also activated by trypsin via peptide cleavage (ENGELHARDT and 
BREVES 2000). 
 
2.1.3 Small Intestinal Physiology 
The small intestine is primarily responsible for nutrient digestion and absorption (CAMPBELL 
and REECE 2003). The acidic chyme from the stomach is released into the duodenum, where 
it mixes with digestive juices from the pancreas, liver, and gallbladder. 
The small intestinal mucosa has a very large surface area. Broad folds and finger-like extrusions 
(intestinal villi) of the mucosa contribute to the enlarged surface area. Further, each epithelial 
cell of the intestinal villi carries microscopic microvilli, which protrude from the luminal cell 
surface into the intestinal lumen (CAMPBELL and REECE 2003). The center of each intestinal 
villus harbors a network of blood capillaries and a central lymphatic vessel. Nutrient products 
absorbed via the intestinal epithelium are transported through the endothelium of the capillaries 
or lymphatic vessels (CAMPBELL and REECE 2003). 
Fluid secretion in the small intestine plays a central role in absorptive processes. Chloride is 
primarily released into the intestinal lumen through a chloride channel in the apical membrane 
of the epithelium. Sodium and potassium follow paracellularly through the zonulae occlud-
entes, driven by an electrical gradient (ENGELHARDT and BREVES 2000). By activating 
chloride and sodium channels, the electrolyte- and osmotically-driven intestinal secretion of 
water can be stimulated (ENGELHARDT and BREVES 2000). Three intracellular second-mes-
senger systems regulate the secretion of chloride from the intestinal epithelial cells: cAMP-, 
cGMP-, and calcium-signaling pathways. These, in turn, offer different pathomechanisms for 
chloride hypersecretion. cAMP directly promotes the secretion of chloride by triggering the 
opening of chloride channels in the brush border membrane (ENGELHARDT and BREVES 
2000). All three signaling pathways also inhibit the absorption of sodium chloride (NaCl). How-
ever, this mechanism is limited to NaCl transport via Na+/H+ and Cl-/HCO3- exchangers and 
does not affect sodium transport via Na+ channels (ENGELHARDT and BREVES 2000). 





2.1.4 Large Intestinal Physiology 
Chyme from the small intestine ultimately enters the large intestine. At the junction between 
these two intestinal portions is a valve-like sphincter that controls the aborad transport of intes-
tinal contents (CAMPBELL and REECE 2003). Major functions of the large intestine include  
the reabsorption of water, including the portion of water presenting the basic substance of di-
gestive secretions (CAMPBELL and REECE 2003). A large part of water absorption occurs 
with the absorption of nutrients in the small intestine, and the colon reabsorbs the remainder of 
the fluid that has remained in the lumen. Together, both small and large intestines reabsorb 
about 99% of the water that enters the alimentary tract (CAMPBELL and REECE 2003). 
Microorganisms colonize the gastrointestinal tract of all mammals immediately after birth, and 
the large intestine is the main site of microbial colonization in monogastric animals (ENGEL-
HARDT and BREVES 2000). The physiologic microbiome includes various species of the gen-
era Bacteroides, Fusobacterium, Streptococcus, Eubacterium, Ruminococcus, Lactobacillus, 
and Treponema, as well as coliforms such as Escherichia coli. Several factors are important to 
maintain a physiologic composition and function of the gastrointestinal (and particularly co-
lonic) microbiome and its metabolic functions (ENGELHARDT and BREVES 2000). These 
include the neutralization of acidic products of microbial metabolism, sufficient residence time 
of the ingesta in the large intestine, dilution of metabolic end-products by the liquid phase of 
colonic content, and resorption of the metabolites from microbial fermentation. Also, the 
gastrointestinal barrier function is important to prevent microbial translocation. 
Goblet cells are mostly located in the large intestine and differ from cells in the small intestine 
or colonic crypts by having numerous mucus-containing secretory granules (ENGELHARDT 
and BREVES 2000). Mucous secretion from goblet cells occurs through a process called col-
lective exocytosis, which is induced by acetylcholine and prostaglandin E (ENGELHARDT 
and BREVES 2000). Mucous secretion is essential for defection. Feces are stored in the distal 
large intestine (rectum) until defecation. This reflex involves two sphincters, an internal (invol-
untary) and an external (voluntary) sphincter located between the rectum and anus (CAMP-
BELL and REECE 2003). Activation of stretch receptors within the rectal wall causes the inner 
sphincter to relax, creating an urge to defecate. Defecation then requires the external sphincter 
to be voluntarily relaxed and increased abdominal pressure (CAMPBELL and REECE 2003). 
 




2.1.5 Gastrointestinal Neuronal and Endocrine System 
The intestinal mucosa has three types of detectors: neuronal, endocrine, and immunological 
(FURGESS et al. 1999). The intrinsic nervous system allows the intestine to autonomously 
regulate its functions depending on the microenvironment, including the amount and type of 
food ingested. The secondary control exerted by the central nervous system on the intestine 
influences the intrinsic systems (nervous and endocrine) and directly regulates intestinal func-
tions (FURNESS et al. 1999). 
The neurons found in the myenteric and submucosal plexus are primary afferent neurons. They 
comprise three different types (FURNESS et al. 1999): (1) intrinsic primary afferent neurons 
comprised of cell bodies and fibers within the gut wall, (2) extrinsic primary afferent neurons, 
with cell bodies in the vagal and dorsal root, and (3) intestinofugal neurons, with cell bodies in 
the muscularis propria and projections to neurons outside the gut wall. 
The intestine produces more than 20 different hormones that are secreted by the enteroendo-
crine cells. One of the most important endocrine mediators is cholecystokinin (CCK). This hor-
mone is released after the ingestion of a meal. CCK mediates the release of digestive enzymes 
from the pancreas and causes bile salts to empty into the duodenum (FURNESS et al. 1999). 
 
2.1.6 Gastrointestinal Immune System 
The gastrointestinal tract has an intrinsic immune system, referred to as the gut-associated lym-
phoid tissue (GALT). The GALT is the most significant accumulation of immune cells within 
the body. Approximately 70% of all immunologically active cells are localized (resident cell 
population) or recruited to the intestinal mucosa. The GALT plays a major role in maintaining 
a delicate balance between mounting an immune response to fight pathogenic microorganisms 
and remaining in an anergic state (immunotolerance) while recognizing a large number of dif-
ferent dietary antigens as well as beneficial organisms of the gut microbiome. The presentation 
of the antigens by antigen-presenting cells (APCs) as structural components of the GALT is a 
fundamental process for the decision between inflammation and immunotolerance (SPAHN 
and KUCHARZIK 2004). Antigen presentation occurs in the intestinal tract, where lymphoid 
follicles of the mucosa are accumulated. The strong presence of these follicles distinguishes the 
GALT from the immune system or immune structures in other parts of the body. The GALT 
functions as the intestinal frontline of the systemic immune response (SPAHN and KU-
CHARZIK 2004). The GALT is comprised of: 
• the tonsils and lymphoid follicles of the palate, 
• the solitary lymph follicles of the intestinal segments, 




• the Peyer’s patches, and 
• the lamina propria of the intestinal segments. 
The mesenteric lymph nodes connect the GALT to the immune system of the body. As part of 
the immune system, tonsils provide an immunity as a first line of defense against ingested or 
inhaled pathogens. The GALT surface contains antigen-capture cells, the so-called M cells, that 
can capture pathogens by detecting specific surface antigens. These M cells function to signal 
the presence of a pathogen to underlying B and T lymphocytes, resulting in the initiation of an 
immune response (KATO et al. 2013). 
 
Peyer’s patches are also an essential structural component of the intestinal immune system. 
These structures play a central role in the surveillance of intestinal bacterial populations and 
preventing intestinal colonization and infection with pathogenic bacteria. The lamina propria 
of the intestinal segments has several immune functions and has a significant role in protecting 
the host from pathogenic microorganisms that can enter from the gastrointestinal tract (VAROL 
et al. 2009). 
 
2.1.7 Innate Immunity and Acquired Immunity 
Mammals have an immune system that includes two main branches: innate immunity and ac-
quired immunity. 
The innate immune system presents the host’s first line of defense against pathogens. Phago-
cytes, including macrophages and dendritic cells, mediate the innate immune response. The 
innate immune system can recognize microorganisms through pattern recognition receptors 
(PRRs), unlike the acquired immune system that contains a vast repertoire of rearranged recep-
tors (AKIRA et al. 2006). 
Acquired immunity plays an essential role in the late phase of the immune response, eliminating 
pathogens at this stage and generating the humoral and cellular immune response as well as 
their cross-talk. This is accomplished through the individual development and separation of 
lymphocytes that carry specific antigen receptors generated by gene rearrangement (AKIRA et 
al. 2006). 
 
2.1.8 Intestinal Microbiome 
The intestinal microbiome consists of bacteria, fungi, viruses, and protozoa (SUCHODOLSKI 
2016). Longitudinal differences are known to exist in the intestinal microbiome, with the large 
intestine harboring a higher number of bacteria (up to 1011 colony-forming units per gram 




[CFU/g]) compared to the small intestine, where the number reaches about 105 CFU/g (SU-
CHODOLSKI 2016). Shotgun deep-sequencing and fluorescence in situ hybridization (FISH) 
analysis allow for the specific identification of most bacterial species. The intestinal microbiota 
is of vital importance to the host. Not only does the physiological microbiome help with intes-
tinal epithelial development and maintenance (homeostasis), but it also constitutes an important 
barrier (or competitor) against pathogenic organisms (SUCHODOLSKI 2016). 
Another important role of the intestinal microbiota is providing nutritional factors to the host, 
including the synthesis of essential vitamins (such as folic acid) and the degradation of poly-
saccharide complexes (NEISH 2009, SWANSON et al. 2011). The latter function also has an 
anti-inflammatory effect by inducing regulatory T lymphocytes (ARPAIA et al. 2013). The 
Firmicutes, Bacteroidetes, Proteobacteria, and Fusobacteria are the most prevalent bacterial 
phyla of the intestinal microbiome in healthy dogs (SUCHODOLSKI et al. 2008; XENOULIS 
et al. 2008, SUCHODOLSKI et al. 2009, HANDL et al. 2011). 
Previous studies demonstrated that the host susceptibility (ALLENSPACH et al. 2010, 
KATHRANI et al. 2012, and KATHRANI et al. 2014) and the intestinal microbiome (XENOU-
LIS et al. 2008, ALLENSPACH et al. 2010, SUCHODOLSKI et al. 2012a, SUCHODOLSKI 
et al. 2012b, HONNEFFER et al. 2014, and MINAMOTO et al. 2015) are of central importance 
in the pathogenesis of chronic inflammatory enteropathies (CIE) in dogs. 
Several recent investigations into the intestinal microbiota of dogs with CIE point to the pres-
ence of an intestinal dysbiosis (SUCHODOLSKI 2016). 
Not only alterations in the interaction of the mucosa and the host’s enteric microbiota but also 
the intestinal microbiota contribute to the pathogenesis of inflammatory bowel disease (IBD) 
in dogs and cats (SUCHODOLSKI 2016). However, it remains to be determined whether these 
changes are a definitive cause or a consequence of IBD (or even a combination of both). 
2.2 Enteropathies in Dogs 
2.2.1 Definition 
Enteropathy refers to any pathology of the intestines. Clinical signs such as vomiting, nausea, 
diarrhea, decreased appetite, or weight loss, amongst others, are described in patients with these 
conditions. Enteropathies can be acute or chronic. 
 
2.2.2. Acute Enteropathy 
Acute diarrhea in dogs is mostly related to dietary or infectious causes. In this species, the 
ingestion of spoiled food, garbage (e.g., containing mold), or substances or things that are not 




suitable for consumption are common causes of acute gastrointestinal signs. Too rapid of a 
change in diet or an intolerance to the type of food offered can also lead to acute diarrhea. Toxic 
reactions (e.g., medications, other toxins) are another common cause of acute diarrhea in dogs 
(LANGLOIS et al. 2019). 
Hypoadrenocorticism (Addison’s disease), especially in its atypical form, can be primarily 
associated with waxing and waning acute or acute-on-chronic gastrointestinal signs. Thus, this 
differential also needs to be considered an extra-gastrointestinal cause of gastrointestinal signs 
mimicking an enteropathy. The exclusion or diagnosis of this condition is by determining a 
serum baseline cortisol concentration and/or an ACTH stimulation test. 
 
2.2.3. Chronic Enteropathies 
Chronic inflammatory enteropathies (CIE) are an important group of gastrointestinal diseases 
in dogs, the diagnosis of which requires (WASHABAU et al. 2010, ALLENSPACH 2016, 
DANDRIEUX 2016): 
• the presence of chronic gastrointestinal signs (≥3 weeks), 
• histopathologic evidence of intestinal mucosal inflammation, and 
• the exclusion of other underlying causes. 
The diagnostic evaluation and patient management can be challenging in dogs with CIE. Canine 
CIE are further subclassified (usually retrospectively) based on the response treatment (Fig. 3). 
 
Figure 3: Frequencies of the different subgroups of chronic inflammatory enteropathies 
(CIE) in dogs. Food-responsive enteropathy (FRE); antibiotic-responsive enteropathy 
(ARE); immunosuppressant-responsive enteropathy (IRE); and non-responsive enteropa-
thy (NRE). 
 




2.2.3.1 Food-Responsive Enteropathy (FRE) 
Dogs showing a significant improvement or resolution of their clinical signs after being placed 
on an elimination diet are classified as FRE. Typically, these dogs are younger and have less 
severe clinical disease than dogs with other CIE forms. FRE is also the most prevalent group 
(approximately 64%; Fig. 3) of CIE in dogs (ALLENSPACH et al. 2016, DANDRIEUX 2016, 
VOLKMANN et al. 2017). 
Treatment of FRE consists of a dietary change to either an elimination diet with a novel protein 
and carbohydrate source (hitherto unknown to the dog) or a hydrolyzed protein diet (that is 
supposed to be less immunogenic). Novel protein/carbohydrate diets can be home-cooked (and 
supplemented/ balanced if considered for long-term feeding) or commercial diets. An excellent 
long-term response in dogs with FRE has been shown with a commercial hydrolyzed protein 
diet (MANDIGERS et al. 2010, ALLENSPACH et al. 2016). It is essential that the owners are 
instructed not to feed any other food source (e.g., table scraps, treats containing other protein 
sources) during an elimination diet trial. 
 
2.2.3.2 Antibiotic-Responsive Enteropathy (ARE) 
Dogs that show a marked and long-lasting improvement or resolution of their clinical signs 
after administering an antibiotic (metronidazole and/or tylosin) for two weeks are classified as 
ARE (DANDRIEUX 2016). Because most dogs that respond to an antibiotic trial will relapse 
after discontinuation of antimicrobial treatment, the true existence of this subgroup of canine 
CIE is currently a matter of debate (ERDMANN and HEILMANN 2017, CERQUETELLA 
2020). 
 
2.2.3.3. Steroid- or Immunosuppressant-responsive enteropathy (SRE/IRE) 
Dogs that require treatment with glucocorticosteroids or other immunosuppressive drugs are 
diagnosed as steroid-responsive (SRE) or immunosuppressant-responsive enteropathy (IRE) 
(ALLENSPACH 2016, DANDRIEUX 2016, ERDMANN and HEILMANN 2017). The diag-
nosis of SRE/IRE is a diagnosis of exclusion. Thus, the diagnostic evaluation of dogs suspected 
to have SRE/IRE can be very complex and present a challenge for both the owners or caretakers 
and the veterinarian. Despite a predisposition in some dog breeds (e.g., German shepherd dog), 
many different breeds of dogs can develop SRE/IRE, which supports the hypothesis of a mul-
tifactorial etiopathogenesis for the development of SRE/IRE in dogs, involving genetic effects 
and environmental factors (Fig. 4). 
 





Figure 4: The pathogenesis of chronic inflammatory enteropathies, particularly SRE/IRE, 
in dogs is multifactorial. Environmental and genetic factors and a dysregulation of the im-
mune system are involved in SRE/IRE E pathogenesis. Heilmann RM, PhD Thesis. Texas 




Like with inflammatory bowel disease (IBD) in human patients, medical treatment of dogs with 
SRE/IRE usually involves the administration of glucocorticosteroids and/or other immunosup-
pressive drugs such as cyclosporine or azathioprine. These drugs can have significant side ef-
fects (ALLENSPACH 2016, DANDRIEUX 2016, ERDMANN and HEILMANN 2017). More 
targeted treatment strategies available in human medicine (e.g., tumor necrosis factor-a block-
ers) would be desirable as a glucocorticosteroid-sparing treatment option for dogs with 
SRE/IRE but are currently lacking in veterinary medicine. 
 
2.2.3.4 Non-Responsive Enteropathy (NRE) 
Studies suggest that approximately 15–40% of dogs with CIE (initially classified as SRE/IRE) 
do not adequately respond to medical therapy, thus worsening the individual prognosis (CRA-
VEN 2004, ALLENSPACH et al. 2007). Whether these patients could potentially benefit from 
additional or alternative immunomodulatory treatment options (including prebiotics, probiot-
ics, or synbiotics; fecal microbiota transplantation [PEREIRA et al. 2017]; stem cell therapy 
[PÉREZ-MERINO et al. 2015a, 2015b]; or a combination of these modalities) requires further 
study. 
 
2.2.3.5 Protein-Losing Enteropathy (PLE) 
Canine PLE is a special form of chronic enteropathies in dogs. This condition can occur sec-
ondary to an infiltrative intestinal disease process (e.g., lymphoplasmacytic enteritis with 




SRE/IRE, or diffuse intestinal neoplasia such as lymphoma) or present a primary intestinal 
lymphangiectasia (with a breed predisposition in Yorkshire Terriers, Rottweilers, Maltese, Ba-
senjis, and Irish Soft Coated Wheaten Terriers). 
As a significant component of the immune system, the lymphatic system is a network of organs, 
lymph nodes, ducts, and lymphatic vessels that produce and transport lymph from the tissues 
to the bloodstream. This system contributes to the extracellular fluid hemostasis, fat absorption 
and transport, and immune system function (CRAVEN and WASHABAU 2018). Mechanisms 
of PLE in dogs involve structural lesions and/or dysfunctions of these lymphatic structures (Fig. 
5). The most common clinical signs shown by affected dogs are chronic vomiting, diarrhea, 
weight loss, loss of lean muscle mass, lethargy, ascites, and/or pleural effusion (DOSSIN and 
LAVOUÉ 2011). Clinicopathological abnormalities can include lymphopenia, 
hypoalbuminemia or panhypoproteinemia, hypocholesterolemia, hypocalcemia/ 
hypomagnesemia, and an increased blood urea nitrogen (BUN) concentration (CRAVEN and 
WASHABAU 2018). 
 
Figure 5: Schematic of the different mechanisms of gastrointestinal protein loss in dogs 
with protein-losing enteropathy (PLE). 
 
 
A rapid diagnostic work-up is desirable and important in dogs with marked hypoalbuminemia 
or panhypoproteinemia, where the risk of complications (e.g., ascites/pleural effusion resulting 
from a marked reduction in plasma colloid-osmotic pressure or thromboembolism associated 




with a hypercoagulability) is also high (DOSSIN and LAVOUÉ 2011, GOODWIN et al. 2011). 
Hypoalbuminemia/panhypoproteinemia and hypovitaminosis D are linked to poor outcomes in 
dogs with PLE (ALLENSPACH et al. 2008, TITMARSH et al. 2015).  Diets that are ultra-low 
in fat (<10–15%) and contain highly digestible proteins are recommended for these patients 
(RUDINSKY et al. 2018, NAGATA et al. 2020), and some dogs diagnosed with PLE will re-
quire additional treatment options to prevent complications of the disease (e.g., anticoagulant 
drugs) or to address the underlying problem (e.g., immunosuppressive drugs). 
Another subtype of PLE in dogs is known as focal lipogranulomatous lymphangitis (FLL). The 
clinical signs of affected dogs are those typically seen with CIE and PLE (vomiting and diarrhea 
for more than three weeks’ duration, and in some cases also weight loss and a profound loss of 
lean muscle mass), and these patients can also be hypoalbuminemic, hypocobalaminemic, or 
both. There may be mesenteric lymphadenopathy, and lymphangiectasia is also common. A 
characteristic finding on abdominal ultrasonography with FLL is an increased intestinal wall 
thickness of the jejunum, ileum, or both with focal or solitary mass-like lesions (Fig. 6) 
(LECOINDRE et al. 2016). The underlying etiology of FLL is unknown, but the current 
consensus is that the pathogenesis – similar to SRE/IRE – involves environmental and genetic 
factors leading to a dysregulated immune response (WATSON et al. 2014, LECOINDRE et al. 
2016). 
 
Figure 6: Lymphangiectasia (yellows arrows) and small multifocal mass (blue arrow) like 
lesions at the serosal aspect of the duodenum in a dog (4- year old male intact Maltese) 
affected with focal lipogranulomatous lymphangitis (FLL). Courtesy of Dr. Cora 
Siebenaller, Small Animal Clinic Marienberg, Germany). 
   
 




2.3  Diagnostic evaluation of dogs with suspected CIE 
A thorough patient medical history is essential in dogs suspected to have a CIE. It should focus 
on information about general clinical signs (diarrhea and vomiting) but also other characteristic 
clinical signs of CIE (e.g., weight loss, smacking while eating or gulping after food intake, 
eating grass, flatulence, salivation, or pica) (ERDMANN and HEILMANN 2017). A complete 
physical examination, including a rectal palpation, should follow, with particular emphasis on 
the presence of abdominal pain, nausea, or ballottement during abdominal palpation 
(WASHABAU et al. 2010, ERDMANN and HEILMANN 2017). 
Given that the clinical signs in dogs with CIE are common to many other diseases, a sequential 
diagnostic evaluation should be initiated, with non-invasive diagnostic tests (including routine 
clinicopathological parameters, fecal parasitology, and diagnostic imaging of the abdomen) 
performed first before more invasive diagnostic tests are being considered. The owners need to 
be educated that the entire process of sequential steps might take some time and require 
patience, increasing owner compliance along that path (WASHABAU et al. 2010, 
DANDRIEUX 2016, ERDMANN and HEILMANN 2017). 
 
2.3.1. Clinical and Clinicopathologic Approach 
A semi-objective method to assess the severity of clinical disease in dogs with suspected or 
confirmed CIE is the use of a clinical disease activity index: the canine inflammatory bowel 
disease activity index (CIBDAI) (JERGENS et al. 2003) or the canine chronic enteropathy 
clinical activity index (CCECAI) (ALLENSPACH et al. 2007). These indices are quantitative 
and repeatable measures that can help assess the clinical disease severity at the time of first 
evaluation and determine the clinical response to treatment (JERGENS et al. 2003). 
The CIBDAI scoring system consists of six clinical parameters (attitude/activity, appetite, 
vomiting, stool consistency, defecation frequency, and weight loss) that are evaluated on a scale 
from 0 (normal) to 3 (severely abnormal). The sum of the results for the individual criteria are 
reported as the cumulative CIBDAI score, where a score of 0–3 reflects clinically insignificant 
disease, a score of 4–5 mild clinical disease, a score of 6–8 moderate clinical disease, a score 
of 9–11 severe clinical disease, and a score of ≥12 very severe clinical disease (ALLENSPACH 
et al. 2007). The CCECAI scoring system is similar to the CIBDAI system. However, it includes 
assessing three additional criteria: serum albumin level, the presence of ascites and/or 
peripheral edema, and pruritus (Table 1). The CCECAI score has predictive value for the 
success of treatment, and a cut-off value of 12 was shown to be the best predictor for a negative 
outcome (ALLENSPACH et al. 2007). 




CCECAI (Canine Chronic Enteropathy Clinical Activity Index) 
Criteria  Assessment 
Attitude/Activity  0 = normal 
  1 = slightly decreased 
  2 = moderately decreased 
  3 = severely decreased 
Appetite  0 = normal 
  1 = slightly decreased 
  2 = moderately decreased 
  3 = severely decreased 
Vomiting  0 = normal 
  1 = mild (1×/wk) 
  2 = moderate (2-3×/wk) 
  3 = severe (>3×/wk) 
Stool consistency  0 = normal 
  1 = slighty soft feces 
  2 = very soft feces 
  3 = watery diarrhea 
Stool frequency  0 = normal 
  1 = slightly increased (2-3×/d) or fecal blood, mucus or both 
  2 = moderately increased (4-5×/d) 
  3 = severely (>5×/d) 
Weight loss  0 = none 
  1 = mild (<5%) 
  2 = moderate (5-10%) 
  3 = severe (10%) 
Serum albumin  0 = serum albumin concentration >20 g/L 
concentration  1 = serum albumin concentraion 15-19 g/L 
  2 = serum albumin concentration 12-14 g/L 
  3 = serum albumin concentration <12 g/L 
Ascites and/or  0 = none 
Peripheral edema  1 = mild ascites or peripheral edema 
  2 = moderate amount of ascites/peripheral edema 
  3 = severe ascites/pleural effusion/peripheral edema 
Pruritus  0 = none 
  1 = occasional 
  2 = regular episodes of itching, but stop when dog asleep 
  3 = dog regularly wakes up because of itching 
Table 1: Individual parameters of the CCECAI scoring system (ALLENSPACH et al. 2007). 
 




Routine clinicopathological parameters are the next diagnostic step, and the minimum database 
(MDB) should consist of a complete blood cell count (CBC), serum biochemistry profile (in-
cluding BUN and creatinine; alanine aminotransferase, alkaline phosphatase, and γ-gluta-
myltransferase activity; total bilirubin, total protein, albumin, total calcium, cholesterol, and 
triglyceride concentrations; sodium, potassium, and chloride concentrations), urinalysis (with 
a urine protein-to-creatinine ratio and/or bacterial culture of urine with antimicrobial 
susceptibility testing, if indicated), and a fecal parasitology (Fig. 7). While there usually will 
be no specific findings pointing to a diagnosis of CIE, the MDB is essential to rule out extra-





Figure 7: Diagnosis scheme for a complete clarification of a chronic enteropathy. 
 
 
A gastrointestinal profile can be performed to further evaluate the dog for pancreatic and 
chronic small intestinal disease. Serum canine trypsin-like immunoreactivity (cTLI) can rule 
out a diagnosis of exocrine pancreatic insufficiency (EPI) (ERDMANN and HEILMANN 
2017). Serum specific canine pancreatic lipase (Spec cPL) concentration is a marker for pan-




creatitis (ERDMANN and HEILMANN 2017). The water-soluble B vitamins cobalamin (vita-
min B12) and folic acid (vitamin B9) are markers of gastrointestinal absorptive function (see 
2.3.3.1. and 2.3.3.2.) (ERDMANN and HEILMANN 2017, KATHER et al. 2020). An increased 
serum Spec cPL concentration is a negative prognostic factor in dogs with CIE, specifically 
SRE/IRE (KATHRANI et al. 2009). A serum baseline cortisol concentration (and if indicated, 
an ACTH stimulation test) can help exclude atypical hypoadrenocorticism (atypical Addison’s 
disease) as a differential diagnosis (LATHAN and THOMPSON 2014), and a bile acid stimu-
lation test can be used to further evaluate the patient for a possible hepatopathy (Fig. 7). 
 
2.3.2. Diagnostic Imaging of the Abdomen 
Another critical part of the diagnostic work-up of dogs with suspected CIE is abdominal 
imaging. Abdominal radiographs can be useful to rule out other disease processes (e.g., chronic 
gastrointestinal foreign bodies, large intraabdominal masses, or decreased serosal detail with 
the presence of ascites). Abdominal ultrasonography is a more sensitive technique to evaluate 
the gastrointestinal tract, mesenteric lymph nodes, liver, and pancreas. Structural changes of 
organs (e.g., intestinal wall thickness or loss of layering, intussusceptions, or solitary neoplasia) 




Figure 8: Abdominal ultrasonography in a dog with PLE due to SRE/IRE. Increased intes-
tinal wall thickness (characterized predominantly by an enlarged mucosal layer) and a scant 
amount of free peritoneal fluid surrounding the intestinal loops are seen. Hyperechogenic 
striations oriented perpendicular to the intestinal lumen are also detected within the mu-
cosa. © Small Animal Clinic, Veterinary Teaching Hospital, College of Veterinary Medi-
cine, University of Leipzig. 
 





Figure 9: Abdominal ultrasonography in a dog with PLE. A generalized hyperechogenicity 
is noted throughout the abdominal cavity. Anechoic free peritoneal fluid surrounding the 
intestinal loops is also detected. The mucosa is diffusely thickened (with the intestinal wall 
layering being preserved) and has a heterogeneous appearance with multifocal hyperecho-
genic areas (stipples). © Small Animal Clinic, Veterinary Teaching Hospital, College of 
Veterinary Medicine, University of Leipzig. 
 
 
2.3.3 Laboratory Tests for Gastrointestinal Disease 
Several biomarkers of gastrointestinal function, inflammation, or protein loss can be useful sur-
rogate tests in the clinical evaluation or monitoring of dogs with suspected or confirmed CIE 
(HEILMANN and STEINER 2018). These biomarkers include serum cobalamin (vitamin B12), 
folate (vitamin B9), and C-reactive protein (CRP) concentrations; and serum and fecal calpro-
tectin (S100A8/A9 complex), S100A12 protein, and alpha1-proteinase inhibitor (α1PI) concen-
trations (JERGENS et al. 2010, HEILMANN et al. 2014a, HEILMANN et al. 2016a, HEIL-
MANN et al. 2018). Notably, decreased serum concentrations of cobalamin and albumin are 
negative prognostic indicators in canine CIE (ALLENSPACH et al. 2007). 
 
2.3.3.1 Serum cobalamin (vitamin B12) 
Vitamin B12 exerts its effect on various cobalamin-dependent enzymes. This vitamin plays an 
essential role as a cofactor of the methylmalonyl-coenzyme A-mutase, necessary for the trans-
formation of propionate to succinate, and tetrahydrofolate-methyltransferase, which is essential 
in the metabolism of methionine. 
Cobalamin is bound to dietary proteins and is digested in the proximal gastrointestinal tract 
(stomach and duodenum) by gastric and pancreatic proteases. Because cobalamin cannot be 




absorbed in its unbound (free) form, it must be complexed to a specific glycoprotein, the intrin-
sic factor (IF). In dogs, it is predominantly produced by the exocrine pancreas. The cobalamin-
IF complex is then absorbed in the distal small intestine (ileum). Dogs, unlike ruminants and 
other herbivores, are not able to synthesize cobalamin. Thus, cobalamin has to be either ingested 
with the diet or supplemented in canines (KATHER et al. 2020). 
Hypocobalaminemia or cobalamin deficiency can indicate a chronic enteropathy involving at 
least the distal small intestine (BATT et al. 1982, KATHER et al. 2020). However, no further 
conclusions regarding the type of chronic enteropathy (e.g., CIE versus small-cell intestinal 
lymphoma), disease extent and severity, or disease location(s) can be drawn from the serum 
cobalamin concentration alone (KATHER et al. 2020). Also, a normal serum cobalamin status 
does not exclude the possibility of a chronic intestinal disease process (ERDMANN and HEIL-
MANN 2017). Hypocobalaminemia in dogs with CIE is defined as a serum cobalamin concen-
tration <350–400 ng/L (KATHER et al. 2020). Cobalamin supplementation (parenteral or oral 
route) is indicated in dogs with a suboptimal serum cobalamin status (KATHER et al. 2020). 
Hypercobalaminemia (without prior supplementation) is infrequently seen in dogs with CIE, 
but the clinical or prognostic importance of this finding remains to be elucidated (SIELSKI et 
al. 2020). 
In patients with a serum cobalamin concentration of less than 400 ng/L, cyanocobalamin sup-
plementation is recommended. Two supplementation protocols exist, via parenteral and oral 
route. The dose of cobalamin does not vary between protocols and is recommended at 50 µg/kg. 
With the parenteral protocol, cobalamin is administered weekly for at least 6 weeks and another 
dose one month later (KATHER et al. 2020). Oral administration of cobalamin is daily over at 
least 12 weeks (KATHER et al. 2020). Serum cobalamin concentration should be checked one 
month after the last dose. 
 
2.3.3.2. Serum folic acid (vitamin B9) 
Folic acid is also a water-soluble B vitamin involved in tissue growth and cell division (e.g., 
erythrocyte formation) in the body. This vitamin is abundant in commercial dog foods. Thus, a 
dietary deficiency is extremely rare in dogs. Hypofolatemia or folic acid deficiency is an 
indicator of chronic disease affecting the proximal small intestine (BATT et al. 1982, 
HEILMANN and STEINER 2018). 
Because folic acid acts as a cofactor in some cobalamin-dependent enzymatic processes, it can 
accumulate in cobalamin deficiency states, resulting in falsely higher (or falsely normal) serum 
concentrations of folic acid (ERDMANN and HEILMANN 2017). 




Folic acid supplementation (200–400 µg once daily for 7–28 days) is recommended for dogs 
with moderate to marked hypofolatemia. 
 
2.3.3.3. Serum C-reactive protein (CRP) 
CRP is produced by hepatocytes due to systemic inflammation, and this biomarker has no 
specificity for the gastrointestinal tract. A previous study (JERGENS et al. 2003) found a 
correlation between the severity of clinical disease activity and the concentration of CRP in 
serum and that serum CRP concentrations decrease with a successful response to 
immunomodulatory treatment. However, other studies (ALLENSPACH et al. 2007, OTONI et 
al. 2017) contradict these findings because the decrease in serum CRP concentrations was not 
directly related to the clinical improvement of patients, given that an increase in CRP in serum 
can be influenced by different causes including infectious, neoplastic, and inflammatory 
conditions (BUSER et al. 2019). 
 
2.3.3.4. Fecal calprotectin and S100A12 protein 
Calprotectin, also known as the S100A8/A9 protein complex, is released from neutrophils and 
activated macrophages, whereas S100A12 is a proinflammatory protein secreted by granulo-
cytes (FOELL et al. 2008, FOELL et al. 2009). If measured in serum, both biomarkers are not 
specific for a particular (localized) inflammatory disease. However, both markers (if increased) 
can indicate an acute or chronic gastrointestinal inflammatory process (HEILMANN and 
STEINER 2018). Dogs with CIE also have increased mucosal expression levels of calprotectin 
and S100A12 compared to healthy individuals (HEILMANN et al. 2019). Measurement of 
calprotectin concentrations in feces can help detect dogs with CIE and predict a suboptimal 
clinical response to treatment in dogs with SRE/IRE (HEILMANN et al. 2018). Fecal concen-
trations of S100A12 can also indicate intestinal inflammation and severe endoscopic lesions in 
the small intestine in dogs and help distinguish FRE cases from SRE/IRE (HEILMANN et al. 
2016). 
 
2.3.3.5. Fecal alpha1-proteinase inhibitor (α1PI) 
In contrast to albumin, alpha1-proteinase inhibitor (α1PI) is not enzymatically degraded during 
the intestinal passage. This allows for the extraction and quantification of α1PI in fecal samples 
(HEILMANN et al. 2011). Fecal α1PI concentrations reflect histopathological lesions in the 
intestinal mucosa that are typically seen with a PLE (lacteal dilation, crypt abscesses). Increased 




fecal α1PI concentrations can be used as an early indicator of gastrointestinal protein loss before 
clinical or clinicopathological signs of a PLE occur (HEILMANN and STEINER 2018). 
 
2.4 Gastrointestinal Histopathology 
Obtaining gastrointestinal tissue biopsies is needed to document inflammation and assess the 
quality and severity of inflammatory infiltration. The quality of tissue samples and the goal to 
obtain samples representing mucosal lesions in the sampled segments of the gastrointestinal 
tract is critical to arriving at a definitive and correct diagnosis in any disease of the digestive 
tract (WILLARD et al. 2008). Gastrointestinal tissue biopsies can be obtained by choosing one 
of three different methods: endoscopic biopsy, laparoscopic biopsy, or a surgical approach via 
celiotomy. Each method of biopsy has advantages and disadvantages. 
An advantage of endoscopy over surgical biopsy is the visualization of the intestinal mucosa 
allowing the endoscopist to obtain samples directly from affected and macroscopically normal 
areas (Fig. 10). 
 
 
Figure 10: Endoscopic view of the duodenum in a dog with protein-losing enteropathy 
(PLE). The multifocal white spots represent macroscopically enlarged lacteals (intestinal 
mucosal lymphangiectasia). © Small Animal Clinic, Veterinary Teaching Hospital, 
College of Veterinary Medicine, University of Leipzig. 
 
 Further, endoscopy allows for the acquisition of multiple (at least 10–15) mucosal biopsies that 
may be more representative of the lesions in the sampled segment than an individual full-
thickness biopsy. Endoscopy also has a minimal risk of perforation (WOOLHEAD et al. 2020). 
However, the disadvantages of endoscopy are that superficial mucosal samples are obtained 




with the potential to miss some pathologies. Laparoscopy or celiotomy allows for full-thickness 
gastric and small intestinal biopsies to be obtained and other intraabdominal organs (e.g., liver, 
pancreas, or lymph nodes) to be sampled but is more invasive and carries the risk of suture 
dehiscence. Also, anti-inflammatory or immunosuppressive treatment may be delayed with this 
approach (ERDMANN and HEILMANN 2017). 
Histopathologic evaluation of gastrointestinal tissue biopsies is performed according to the En-
doscopic, Biopsy, and Histopathologic Guidelines for the Evaluation of Gastrointestinal In-
flammation in Companion Animals established by an initiative of the World Small Animal Vet-
erinary Association (WSAVA) Gastrointestinal Standardization Group and released by the 
American College of Veterinary Internal Medicine as a consensus statement (WASHABAU et 
al. 2010). Using this standard histopathologic evaluation scheme (DAY et al. 2008), each of the 
inflammatory and structural criteria are assessed and assigned a score between 0 (normal) and 
3 (severely abnormal) (WASHABAU et al. 2010, DAY et al. 2008): 
• score 0 = normal 
• score 1= mildly abnormal 
• score 2 = moderately abnormal 
• score 3 = severely abnormal. 
However, the recognition and interpretation of inflammatory and structural changes in endo-
scopic biopsies can be challenging even for board-certified and experienced veterinary 
pathologists (WILLARD et al. 2002 and 2010). Also, normal gastrointestinal histology can be 
affected by various factors (e.g., age, diet, medications) that can vary from patient to patient 
(BAUM et al. 2007). 
 
2.5 Pattern Recognition Receptors 
The innate immune system is equipped with receptors called pattern recognition receptors 
(PRRs). These receptors recognize exogenous pathogen-associated molecular pattern (PAMP) 
molecules as well as endogenous damage-associated molecular pattern (DAMP) molecules 
(HEILMANN and ALLESPACH 2017). There are many different PRRs, for example, Toll-like 
receptors (TLR) such as TLR1, TRL2, TLR3, TLR4, TLR5, TLR6, TRL7, TLR8, TLR9, 
TLR10, TLR11, TLR12, and TLR13, nucleotide-binding oligomerization domain (NOD)-like 
receptors such as NOD2, and the receptor for advanced glycation end products (RAGE). PRRs 
can be located either on the cell surface (e.g., full-length RAGE, TLR 4, or TLR 5) or within 
cells (e.g., NOD2) (HEILMANN and ALLENSPACH 2017). PRRs generally consist of several 
domains but have an individual sequence of different domains and associated functions. 




Dysregulations in the signaling cascades of PRRs have been linked to the development of 
chronic primary inflammatory or autoimmune diseases (BIERHAUS et al. 2005, WALSH et 
al. 2013). The innate immunity also appears to play a key role in the complex pathogenesis of 
CIE in dogs (JERGENS and SIMPSON 2012, HEILMANN and SUCHODOLSKI 2015, 
SCHMITZ et al. 2015, HEILMANN and ALLESPACH 2017). Genomic and also functional 
dysregulations have been demonstrated for TLR2, TLR4, and TLR9 (genetic polymorphisms 
and increased mucosal expression), TLR5 (genetic polymorphisms and decreased mucosal 
expression), NOD2 (single-nucleotide polymorphisms), and soluble RAGE (decreased serum 
levels) in dogs with CIE (ALLENSPACH et al. 2010, KATHRANI et al. 2012, KATHRANI et 
al. 2014.) and some of these changes were related to the clinical disease activity (assessed by 
the CCECAI scoring system). These findings agree with genetic polymorphisms and functional 
aberrations in human patients with IBD (Crohn’s disease and ulcerative colitis) (HEILMANN 
and ALLENSPACH 2017). Further research in the area of PRR in canine CIE is warranted to 
better characterize the innate immune arm of CIE pathogenesis and explore potential novel (and 
more targeted) treatment strategies (HEILMANN and ALLESPACH 2017). 
 
2.5.1 Receptor for Advanced Glycation End Products 
The receptor for advanced glycation end products (RAGE) belongs to the group of innate 
immune PRRs. It can recognize both exogenous PAMPs and endogenous DAMPs released with 
inflammation and tissue damage (BIERHAUS et al. 2005, HEILMANN and ALLENSPACH 
2017). 
The complete (full-length) or transmembrane form of RAGE (Fig. 11) consists of five receptor 
domains (HEILMANN and ALLENSPACH 2017): 
• 1 variable (V-type) domain for ligand binding, 
• 2 constant (C-type) domains, 
• 1 transmembrane domain (anchor), and 
• 1 cytoplasmic tail domain (which initiates post-receptor signaling). 
Full-length RAGE is a type I transmembrane glycoprotein that is constitutively expressed on 
the surface of certain cells (e.g., alveolar cells). In contrast, its expression in other cells (e.g., 
macrophages) is induced by the accumulation of RAGE ligands (i.e., the existence of a proin-
flammatory microenvironment) or the activation of certain transcription factors (e.g., nuclear 
factor-κB) (BIERHAUS et al. 2005, MEIJER et al. 2014, HEILMANN and ALLENSPACH 
2017). In addition to the complete transmembrane (full-length) receptor, there are soluble forms 
of RAGE (sRAGE) from which the cytoplasmic portion is missing. Soluble RAGE functions 




as a decoy receptor through its ability to bind and capture proinflammatory RAGE ligands (Fig. 
12). The canine RAGE gene and its gene products have been characterized, and there are 24 
currently known variants of this receptor in dogs (STERENCZAK et al. 2009). 
 
Figure 11: Structure of the transmembrane (full-length) receptor for advanced glycation 
end products (RAGE). 
 
 
RAGE plays an important role in the pathogenesis of chronic inflammatory diseases in humans. 
Sustained RAGE-ligand interaction was suggested to be associated with the perpetuation and 
amplification of the proinflammatory immune response in autoimmune diseases, such as human 
IBD (BIERHAUS et al. 2005). Shortened isoforms of RAGE, such as the decoy receptor 
sRAGE that result from alternative splicing or proteolytic cleavage (MEIJER et al. 2014, HEIL-
MANN and ALLENSPACH 2017) can abrogate the RAGE-ligand interaction (Fig. 12) and 
thus modulate downstream signaling (BIERHAUS et al. 2005). 
A recent study that investigated the intestinal expression of RAGE in human IBD and also the 
effect of RAGE-blockade by the specific inhibitor FPS-ZM1 (N-Benzyl-N-cyclohexyl-4-
chlorobenzamide) in a murine experimental model of human IBD (BODY-MALAPEL et al. 
2019) showed RAGE to be expressed in the colon and small intestine in people as well as in 
mice and to be upregulated with inflammatory conditions (Crohn’s disease and ulcerative 
colitis). RAGE-blockade by FPS-ZM1 administration was associated with less severe enteritis 




in the ileum and jejunum (BODY-MALAPEL et al. 2019). FPS-ZM1 binds specifically to 
domain 5 and blocks RAGE-binding of some DAMPs (e.g., S100B and high-mobility group 
box 1 [HMGB1] protein). Thus, further investigation of the RAGE/sRAGE axis might be a 
valuable in the ileum and jejunum (BODY-MALAPEL et al. 2019). FPS-ZM1 binds 
specifically to domain 5 and blocks RAGE-binding of some DAMPs (e.g., S100B and high-
mobility group box 1 [HMGB1] protein). Thus, further investigation of the RAGE/sRAGE axis 
might be a valuable route to explore potential novel therapeutic strategies (BODY-MALAPEL 




Figure 12: Soluble RAGE (sRAGE) competes with complete (full-length) transmembrane 
RAGE for ligand binding. Modified from: Heilmann RM, PhD Thesis, Texas A&M Uni-
versity, TX, USA (2015). 
 
The expression of RAGE has also been investigated in canine lymphoma and histiocytic sar-
coma (STERENCZAK et al. 2010, STERENCZAK et al. 2011). In the last study, 
STERENCZAK et al. (2011) showed that the RAGE-HMGB1 complex plays an important role 
in the maturation, migration, and immune response of dendritic cells. This finding suggests that 
the dysregulation of RAGE pathways is involved in the progression of histiocytic disorders 
such as disseminated histiocytic sarcoma (a very aggressive neoplasm of dendritic cells) in 
dogs. Dysregulations of RAGE-HMGB1 are also associated with other neoplastic conditions in 
humans (e.g., cholesteatoma and pancreatic, prostate, and colonic neoplasia) (SCZPANSKI et 
al. 2014 and ZHAO et al. 2014). 
Conversely, downregulation of RAGE expression has been demonstrated in non-small cell lung 
cancer (BARTLING et al. 2005). Less RAGE expression was associated with higher 
histological stages of cancer and overexpression of RAGE with decreased tumor growth. This 




suggests RAGE regulation to differ between different tissues (e.g., lung versus hematopoietic 
or histiocytic cells) and linked to physiological levels of post-natal RAGE expression in these 
tissues. 
A previous pilot study in dogs showed that serum sRAGE concentrations are significantly (and 
in some cases severely) decreased with CIE, particularly SRE/IRE, compared to serum sRAGE 
levels in healthy dogs (HEILMANN et al. 2014b). It was hypothesized that this finding results 
from an increased consumption of this decoy receptor (i.e., an attempt to abrogate intestinal 
proinflammatory RAGE signaling) in affected dogs. However, it is also possible that serum 
sRAGE deficiency contributes to the pathogenesis of canine CIE or SRE/IRE. Interestingly, the 
same study showed that serum sRAGE concentrations increased or returned to normal (i.e., 
serum sRAGE levels detected in healthy controls) only in dogs that achieved clinical remission 
during the induction phase of treatment (HEILMANN et al. 2014b). However, intestinal tissue 
RAGE expression has not been investigated in canine CIE. Research to further investigate the 
RAGE/sRAGE axis and its potential for developing targeted (pathway-specific) treatment op-
tions in canine CIE – a good spontaneous model for human IBD (JERGENS and SIMPSON 
2012) – might also benefit human IBD research. 
2.6 Aims and Hypotheses 
The aim of this study is to determine serum sRAGE concentrations in canine CIE and their 
association with histological and clinicopathological evidence of CIE, including serum and fe-
cal biomarkers of gastrointestinal inflammation or protein loss. Further, the expression of full-
length RAGE along the gastrointestinal tract (stomach, duodenum, ileum, and colon) is evalu-
ated in canine CIE by immunofluorescence analysis. Quantitative expression of RAGE in the 
gastrointestinal epithelium in dogs with CIE is compared to gastrointestinal RAGE expression 
levels in healthy control dogs. It is evaluated for the possibility of an association with serum 
sRAGE concentrations and with clinical, clinicopathological, and histological markers of gas-
trointestinal disease. 
The study evaluates the hypothesis that (1) gastrointestinal epithelial RAGE is overexpressed 
in dogs with CIE and (2) gastrointestinal epithelial RAGE expression and serum sRAGE 
concentrations correlate with the severity of clinical, clinicopathologic, and histologic evidence 





3 OWN PUBLICATIONS 
My contribution to this part of the dissertation consisted of staining tissue samples and evalu-
ating the intestinal mucosal expression of RAGE (receptor for advanced glycation end-prod-
ucts), analyzing patient data and disease outcomes, and interpreting the results of the statistical 
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Abstract. Innate immunity plays a central role in the pathogenesis of chronic inflammatory 
enteropathies (CIE) in dogs, and further evaluation of the innate immune receptor for advanced 
glycation end-products (RAGE) is warranted. We measured serum concentrations of decoy re-
ceptor soluble RAGE (sRAGE) in 102 dogs diagnosed with CIE, and evaluated relationships 
with clinical disease severity, histologic lesion severity, concentrations of serum C-reactive 
protein (CRP), and serum and fecal calprotectin, S100A12, and alpha1-proteinase inhibitor 
(α1PI). Serum sRAGE levels were not associated with clinical disease activity, serum CRP, 





odenum were more severe in dogs with serum sRAGE concentration ≤340ng/L (p=0.013). Se-
rum sRAGE levels were weakly and inversely correlated with the severity of lympho-
plasmacytic infiltration in the gastric antrum and duodenum, and with crypt dilation and the 
neutrophilic infiltrate in the duodenum, in univariate analysis (all p<0.05), but none of the cor-
relations remained statistically significant after correction for multiple comparisons. Our study 
confirms that CIE in dogs is associated with decreased serum sRAGE concentrations, suggest-
ing a dysregulated sRAGE/RAGE axis. 
Key words: canine; ELISA; inflammatory bowel disease; innate immunity; pattern recognition 
receptor; RAGE; receptor for advanced glycation end-products. 
 
Introduction 
Chronic inflammatory enteropathies (CIE) are important diseases in dogs, the diagnosis of 
which requires the presence of chronic gastrointestinal signs (≥ 2 wk), histopathologic evidence 
of intestinal mucosal inflammation, and the exclusion of other underlying causes.2,8,34 Canine 
CIE are classified based on response to dietary changes (food-responsive enteropathy, FRE) 
and antibiotic trials (antibiotic-responsive enteropathy), or the response to anti-inflammatory 
or immunosuppressive treatment (immunosuppressant-responsive or -refractory enteropathy, 
IRE).2,8,10 Several biomarkers of inflammation have been evaluated in dogs with CIE,21 of 
which C-reactive protein (CRP), calprotectin (S100A8/A9 protein complex), S100A12 (cal-
granulin C) protein, and alpha1-proteinase inhibitor (α1PI) appear to have clinical util-
ity.14,17,20,23 Similar to inflammatory bowel disease (IBD) in humans, medical treatment of dogs 
with IRE usually involves corticosteroids and/or other immunosuppressive drugs;2,8,10 more 
targeted treatment strategies would be desirable but are currently lacking. 
Dysregulations of the innate immune response, in particular the signaling cascades of pattern 
recognition receptors (PRRs), have been linked to the development of chronic autoimmune 
diseases.3,32 The innate immune system plays a key role in the complex pathogenesis of 
CIE,16,19,27,34 and there is also evidence of PRR dysregulation in dogs with IRE.19 Further re-
search in this area is needed to better characterize the pathogenesis of CIE and to aid in the 
development of more targeted treatment strategies.19 
The receptor of advanced glycation end-products (RAGE) is a PRR that recognizes pathogen-
associated molecular patterns and endogenous molecular structures released at sites of inflam-
mation or tissue damage.3,19,32 Full-length RAGE is a type I transmembrane glycoprotein that 
is constitutively expressed on the surface of certain cells (e.g., alveolar cells); its expression in 
other cells (e.g., macrophages) is induced by the accumulation of RAGE ligands (i.e., existence 
of a proinflammatory microenvironment) or the activation of certain transcription factors (e.g., 
nuclear factor–κB).3,19,25 Sustained RAGE-ligand interaction was suggested to be associated 
with the perpetuation and amplification of the proinflammatory immune response in autoim-
mune diseases, such as human IBD.3,26 Shortened isoforms of RAGE, such as the decoy recep-





can abrogate the RAGE-ligand interaction and thus modulate downstream signaling.3,26 A 2019 
experimental study also indicated that the RAGE signaling pathway plays a key role in intesti-
nal inflammation as it promotes oxidative stress and endothelial activation, and that interference 
with the RAGE pathway presents a promising therapeutic target in patients with IBD.4 
 
 
Figure 1. Intestinal mucosal expression of the receptor for advanced glycation end-products (RAGE). Fluores-
cence microscopy image of a colonic mucosal biopsy obtained from a dog diagnosed with moderate diffuse lym-
phoplasmacytic and eosinophilic chronic colitis. The image shows multifocal positive immunostaining (pink flu-
orescence; arrows) for RAGE that is located predominantly in the colonic epithelium. Bar = 50µm. Inset: repre-
sentative negative control (primary antibody omitted) confirming absence of nonspecific staining. Arrows indicate 
artificial autofluorescence caused by erythrocytes. Bar = 50 µm. 
 
The canine RAGE gene and its gene products have been characterized,28 and the expression of 
RAGE in canine lymphoma and histiocytic sarcoma has been evaluated.29,30 RAGE is also ex-
pressed in the intestinal mucosa in dogs (Fig. 1). In a pilot study, serum sRAGE concentrations 
were decreased in a small group of dogs with CIE compared to healthy controls and normalized 
only in those dogs that experienced full clinical remission during the induction phase of ther-
apy.15 However, the association between serum sRAGE, disease severity, and other inflamma-
tory biomarkers has not been studied extensively in canine CIE. Thus, further evaluation of the 
sRAGE/RAGE axis in canine CIE is warranted. We hypothesized that serum sRAGE concen-
trations in dogs with CIE correlate with 1) the severity of clinical signs, 2) the severity of mi-
croscopic lesions, and 3) with the concentrations of serum and fecal biomarkers of inflamma-
tion or protein loss. To test these hypotheses, we evaluated serum sRAGE concentrations in a 
large group of dogs with CIE and correlated serum sRAGE concentration with 1) a clinical 
disease activity score, 2) a histologic disease score, and 3) the concentrations of serum CRP 








Materials and methods 
Ethics approval 
Our study was approved by the Clinical Research Review Committee (CRRC approval TAMU 
2009-06, approved 01-15-2009) and the Institutional Animal Care and Use Committee at Texas 
A&M University (IACUC approval TAMU 2012-083, approved 05-22-2012). A letter of in-
formed consent was signed by the owner to enroll dogs in the study. 
Study population 
We included 102 dogs diagnosed with CIE in our study (Fig. 2). These dogs were enrolled over 
a 61-mo period (Sept 2009– Oct 2014) and were recruited at the Veterinary Teaching Hospital 
at Texas A&M University (College Station, TX; n = 6) or at one of several small animal referral 
hospitals across the United States (n = 96). Inclusion criteria were the presence of gastrointes-
tinal clinical signs for at least 2–3 wk, exclusion of other identifiable causes (i.e., atypical hy-
poadrenocorticism, exocrine pancreatic insufficiency), and intestinal mucosal infiltration with 
inflammatory cells confirmed by histopathology.34 There were no restrictions on canine breed 
or age. The exclusion criteria were the diagnosis of other causes of the gastrointestinal clinical 
signs (e.g., alimentary lymphoma), the lack of gastrointestinal tissue biopsies, or insufficient 
sample material for serum sRAGE analysis. Some of the data from these dogs have been pub-
lished previously.20 
Routine diagnostic investigation of dogs included a physical examination; hematology (per-
formed at the institution recruiting the case or at the Texas Veterinary Medical Diagnostic La-
boratory), serum biochemistry profile (LiquiColor, Sirrus clinical chemistry analyzer; Stanbio 
Laboratory) with a bile acid stimulation test or an ACTH stimulation test if indicated, and uri-
nalysis (with a urine culture and/or a urine protein-to- creatinine ratio if indicated); fecal endo-
parasite screen; abdominal diagnostic imaging (ultrasonography and/or radiographs); a gastro-
intestinal profile including serum canine trypsin-like immunoreactivity (cTLI), specific canine 
pancreatic lipase (Spec cPL), cobalamin (n = 101), folate (n = 101), and gastrin concentration. 
Hypoalbuminemia was defined as mild (serum albumin concentration 15–20 g/L), moderate 
(12–14.9 g/L), or severe (< 12 g/L), and dogs with a serum cobalamin concentration < 300 ng/L 
were classified as hypocobalaminemic. 
At the time of evaluation, each patient (except for one dog) was assigned a canine chronic 
enteropathy clinical activity index (CCECAI) score,1 which considers the general attitude and 
activity of the dog, appetite, frequency of vomiting, stool consistency and frequency of defeca-
tion, weight loss, serum albumin concentration, peripheral edema or ascites, and pruritus. Indi-
vidual CCECAI criteria can range from 0–3 (0 = normal, 1 = slightly abnormal, 2 = moderately 
abnormal, 3 = severely abnormal), and the cumulative CCE- CAI score is interpreted as clini-
cally insignificant disease (score 0–3), mild disease (score of 4–5), moderate disease (score of 
6–8), severe disease (score of 9–11), or very severe disease (score of ≥ 12).1 
Endoscopy of the gastrointestinal tract (n = 94) or laparotomy (n = 8) with collection of tissues 





the gastrointestinal tract (stomach— range: 1–24, median: 12; duodenum—range: 1–29, me-
dian: 13; ileum—range: 1–22, median: 4; colon—range: 1–44, median: 14). The tissue samples 
were subjected to routine histologic evaluation,9,34 through the Texas A&M University. Gas-
trointestinal Laboratory Histopathology service and were evaluated by 1 of 9 board-certified 
anatomic pathologists with special expertise in small animal gastrointestinal pathology. Tissue 
biopsies were histologically evaluated using the structural and inflammatory criteria of the 
World Small Animal Veterinary Association Gastrointestinal Standardization grading sys-
tem.9,34 A score of 0 was assigned to normal tissues, 1 for mild histologic lesions, 2 for moderate 
histologic lesions, and 3 for severe histologic changes. Individual and cumulative lesion scores 
(calculated as the sum of individual lesion scores of the stomach, duodenum, ileum, and colon) 
were considered for data and statistical analyses. 
 
 
Figure 2. Study flowchart. Of the 104 dogs considered for inclusion in the study, 102 dogs were included. Data 
from all 102 dogs were included in the first part of the study (I: correlation with clinical disease severity) and in 
the second part of the study (II: correlation with the severity of histologic lesions); data from a subset of these dogs 
were included in the third part of the study (III: correlation with biomarkers of gastrointestinal inflammation or 
protein loss). Available from 101 dogs.  
Follow-up samples and/or information were available for 20 dogs and for a period of 1–10 mo. 
Patients were diagnosed with FRE based on the clinical response to an elimination diet with a 
protein hydrolysate or a novel protein and carbohydrate source (2 of these 5 dogs had received 





or immunosuppressive treatment were classified as IRE (8 of these 15 dogs also received met-
ronidazole or tylosin as part of their treatment plan). 
Sample collection and analysis  
Serum samples from dogs included in our study were also used for measurement of CRP (n = 
100), calprotectin (n = 55), S100A12 (n = 39), and α PI (n = 99). In addition, calprotectin 1 (n 
= 79), S100A12 (n = 39), and α1PI concentrations (n = 94) were measured in fecal samples 
from 3 consecutive days. Not all markers could be analyzed in samples from all dogs given the 
amount of sampling material available. 
Serum sRAGE concentrations were measured in archived samples (stored at −80°C for 1–72 
mo) by ELISA as described previously.15 Briefly, 96-well plates were coated with 150 ng of 
polyclonal anti-canine RAGE antibody (sheep anti- recombinant canine RAGE; R&D Sys-
tems). Following a wash step, nonspecific binding sites were blocked with 30% (v/v) newborn 
calf serum and 1% (v/v) Triton X-100 (Thermo Fisher) in phosphate-buffered saline (PBS; 
assay buffer). Plates were then incubated with test samples (diluted 1 in 2 [50% each] in assay 
buffer, each sample tested in duplicate), calibrator solutions with different canine RAGE con-
centrations (5,000, 2,000, 1,000, 500, 200, 100, and 20 ng/L in assay buffer), and assay blanks 
(assay buffer). After another wash step, plates were incubated with a biotinylated poly- clonal 
anti-canine RAGE antibody (60 ng/well; R&D Systems) and were washed again. NeutrAvidin–
horseradish peroxidase (NA-HRP; Thermo Fisher Scientific) in PBS with 1% (w/v) bovine se-
rum albumin (20 ng/well) was added to each plate, and after a wash step each well received a 
stabilized 3,3’,5,5’-tetramethylbenzidine substrate. After 10min, the reaction was stopped by 
adding 4M acetic acid, and the absorbance in each well was measured at 450 nm by use of an 
automated plate reader. A 5-parameter logistic curve fit was used to determine canine serum 
sRAGE concentrations in test samples. The limit of detection (LOD) of the assay has previously 
been reported at 52 ng/L.15 
Serum CRP concentrations were measured using a commercial ELISA (Phase CRP; Tri-Delta 
Diagnostic). Calprotectin and S100A12 concentrations in serum and fecal samples were tested 
using previously established and analytically validated species-specific sandwich ELISAs;11,18 
serum and fecal α1PI were measured using an in-house radioimmunoassay.12,13 
Statistical analysis 
Normality of the data and equality of variances were tested by using a Shapiro–Wilk test and a 
Brown–Forsythe test, respectively. Summary statistics are presented as median and interquar-
tile ranges (IQR) or ranges. Serum sRAGE concentrations were compared among the different 
groups of dogs using nonparametric group comparisons (Wilcoxon rank-sum test or Kruskal–
Wallis test with Dunn post-hoc comparisons). A potential relationship of serum sRAGE levels 
with clinical disease activity (CCECAI scoring system), histologic lesion severity (4-point 
semi-quantitative grading system), and serum and fecal inflammatory marker concentrations 
was tested using a likelihood ratio test for association or calculation of a Spearman rank-sum 
correlation coefficient ρ. Sensitivity and specificity were calculated as the true-positive and 





characteristic curve with a Youden index for determination of the optimum cutoff value (con-
tinuous data). Statistical significance was set at p≤0.05, and a Holm sequential Bonferroni cor-
rection was applied for multiple comparisons.22 A commercial statistical software package 
(JMP v.13; SAS) was used for all statistical analyses. 
Results 
Study population 
A total of 102 dogs met the inclusion criteria (Fig. 2, Table 1). Dogs were 4–9y old, and there 
was an approximately even sex distribution. Most dogs were purebred (82%). Clinical disease 
activity (CCECAI) scores and histologic lesions scores varied from mild to severe or very se-
vere. Approximately one third of the dogs were hypoalbuminemic (29%), and 33% of the dogs 
were hypocobalaminemic. 
Serum sRAGE concentrations 
Serum sRAGE concentrations were 52–3,260 ng/L (median: 287ng/L) in all CIE dogs, with 65 
dogs (64%) having a serum sRAGE concentration ≤340ng/L (cutoff value that has previously 
been shown to provide the best separation of CIE dogs from healthy control dogs;15 Table 1). 
Twelve dogs (12%) had a serum sRAGE concentration below the LOD of 52 ng/L. Prior corti-
costeroid treatment (p=0.150, Wilcoxon rank-sum test) or disease duration (p = 0.387, Spear-
man correlation analysis) did not affect serum sRAGE concentrations. Age was also not corre-
lated with serum sRAGE concentrations (ρ=0.16, p=0.108), and serum sRAGE concentrations 
did not differ between purebred (median: 287ng/L, IQR: 153–432ng/L) and mixed-breed (me-
dian: 275 ng/L, IQR: 178–637 ng/L; p = 0.772) dogs. 
 
Table 1. Characteristics of the 102 dogs included in our study of biomarkers of inflammation in cases of canine 
chronic inflammatory enteropathy. 
Group characteristic Value 
Total number 102 
 
Age in years, median (IQR) 6.8 (4–9) 
Sex, male (neutered)/female (spayed) 50 (44)/52 (50) 
Body weight in kg, median (IQR) 14.6 (6.5–24.8)  
Dog Breed, n  
Purebreed  84 (82%) 
German Shepherd  14 (14%) 
Yorkshire Terrier 7 (7%) 
Mixed breed  18 (18%) 
Disease duration in months, median (IQR) 3 (1-8) 
Prior glucocorticosteroid treatment 11 (11%) 
 





Endoscopic  94 (92%) 
Surgical  8 (8%) 
No. of biopsies per site, median (IQR) 
Stomach (n = 89) 12 (10-16) 
   Endoscopic    13 (10-17) 
   Surgical    2 (1-4) 
Duodenum (n = 90) 13 (8- 17) 
   Endoscopic    13 (11-17) 
   Surgical    1 (1) 
Ileum (n = 22) 4 (1–11) 
   Endoscopic    8 (4-14) 
   Surgical    1 (1-2) 
Colon (n = 28) 14 (10-17) 
   Endoscopic    15 (10-17) 
   Surgical    2 (1-2) 
Histologic lesion score, median (IQR) 
Stomach 1 (0–2) 
Duodenum 1 (1–2) 
Ileum 2 (0–2) 
Colon  1 (1–2) 
Overall lesion score 2 (1–2) 
 
CCECAI score, median (IQR)* 7 (5–11) 
Clinical disease severity, n (%) 
Mild† 37 (37%) 
Moderate‡ 21 (21%) 
Severe § 24 (24%) 
Very severe¦ 19 (19%) 
 
Serum sRAGE concentration in ng/L, median (IQR) 287 (154–472) 
Serum sRAGE concentration >340 ng/L, n (%) 37 (36%) 
Serum sRAGE concentration ≤340 ng/L, n (%) 65 (64%) 
   Serum sRAGE concentration 52–340 ng/L, n (%)   53 (52%) 
   Serum sRAGE concentration ≤52 ng/L, n (%)   12 (12%) 
Serum albumin concentration in g/L, median (IQR) 26 (19–30) 
Hypoalbuminemia, n 29 (29%) 
Mild# 14 (14%) 
Moderate 9 (9%) 
Severe** 6 (6%) 
Serum cobalamin concentration in ng/L, median (IQR)* 319 (212–678) 
Hypocobalaminemia††, n  33 (33%) 





Hypofolatemia, n  16 (16%) 
Hyperfolatemia, n  5 (5%) 
Serum CRP concentration in mg/L, median (IQR) (n=100) 8.6 (1.2–26.6) 
Fecal calprotectin concentration in µg/g, median (IQR) (n=79) 1.5 (0.5–17.0) 
Serum calprotectin concentration in mg/L, median (IQR)  (n=55) 6.3 (4.1–8.9) 
Fecal S100A12 concentration in ng/g, median (IQR) (n=85) 131 (21.3–864) 
Serum S100A12 concentration in µg/L, median (IQR)  (n=39) 211 (148–339) 
Fecal α1PI concentration in µg/g, median (IQR) (n=94) 7.4 (3.8–23.8) 
Serum α1PI concentration in mg/L, median (IQR)  (n=99) 1290 (1005–1493) 
CCECAI = canine chronic enteropathy clinical disease activity index; CRP = C-reactive protein; 
IQR = interquartile range. *available from 101 dogs; †CCECAI score of 4–5, ‡CCECAI score of 6–
8, §CCECAI score of 9–11, ¦CCECAI score of ≥12; #defined as a serum albumin concentration 15–
20 g/L; ¶defined as a serum albumin concentration 12–14.9 g/L; **defined as a serum albumin con-
centration <12 g/L; ††defined as a serum cobalamin concentration <300 ng/L 
 
Correlation of serum sRAGE concentrations with clinical and histologic disease severity 
Serum sRAGE concentrations were not associated with the severity of clinical signs (CCECAI 
scores; ρ = −0.07, p = 0.460). A higher maximum overall histologic lesion score was associated 
with a serum sRAGE concentration ≤ 340 ng/L (p=0.028; sensitivity: 73%, specificity: 48%), 
and microscopic lesions in the duodenum were more severe in dogs with serum sRAGE levels 
≤340ng/L (p=0.013; Fig. 3). A cumulative microscopic lesion score in the duodenum of ≥ 4 
was detected by a serum sRAGE concentration of ≤ 340 ng/L with a sensitivity of 57% and a 
specificity of 68%. Serum sRAGE was significantly and inversely correlated with the severity 
of lymphoplasmacytic infiltration in the gastric antrum (ρ = −0.22, p = 0.038) and duodenum 
(ρ = −0.25, p = 0.017), and with crypt dilation (ρ = −0.23, p = 0.027) and neutrophilic infiltrate 
in the duodenum (ρ = −0.21, p = 0.044), in univariate analysis, but none of the results remained 
statistically significant after correction for multiple comparisons (Table 2). No other correla-
tions of histologic criteria with serum sRAGE concentrations were identified. 
 
Correlation of serum sRAGE concentrations with other inflammatory biomarkers 
Serum sRAGE concentrations were not associated with serum CRP concentrations (n = 100; ρ 
= 0.04, p = 0.708), nor with the concentration of serum (n = 55; ρ = −0.08, p = 0.551), or fecal 
calprotectin (n = 79; ρ = 0.12, p = 0.277), or fecal S100A12 (n = 85; ρ = 0.17, p = 0.132). Serum 
sRAGE and S100A12 concentrations were also not significantly correlated (n = 39; ρ = −0.17, 
p = 0.095; Fig. 4). 
 
Correlation of serum sRAGE concentrations with other prognostic markers 
Dogs with more moderate or severe hypoalbuminemia (i.e., a serum albumin concentration < 
15 g/L) had numerically lower serum sRAGE concentrations (median: 242 ng/L, IQR: 76–340 
ng/L) compared to dogs with normoalbuminemia or mild hypoalbuminemia (i.e., a serum albu-
min con- centration ≥ 15 g/L; median: 297 ng/L, IQR: 161–519 ng/L; Fig. 5), but this difference 





sRAGE concentrations between dogs with hypocobalaminemia (i.e., a serum cobalamin con-
centration < 300 ng/L; median: 266 ng/L, IQR: 201–422 ng/L) and dogs with normocobala-
minemia (i.e., serum cobalamin concentrations ≥ 300 ng/L; median: 296 ng/L, IQR: 140– 499 
ng/L; p = 0.891). Also, there was no correlation between serum sRAGE and serum (n = 99; ρ 





Figure 3. Association of gastrointestinal histologic 
lesions with serum soluble RAGE (sRAGE) con-
centrations in dogs with chronic inflammatory en-
teropathy (CIE; n = 102). A. Patients with moder-
ate-to-severe histologic lesions (score 2–3) had nu-
merically lower serum sRAGE concentrations 
(median: 257 ng/L, interquartile range [IQR]: 126–
413ng/L; n=56) compared to dogs with no more 
than mild histologic lesions (score: 0–1; median: 
326 ng/L, IQR: 207–573 ng/L; n=46), but no sig-
nificant difference in serum sRAGE concentration 
was found between the groups of dogs (p=0.157). 
B. Cumulative histologic lesion scores in the duo-
denum in dogs with CIE and a serum sRAGE con-
centration ≤ 340 ng/L were significantly higher 
(median: 4, IQR: 2–6; n = 61) compared to dogs 
with a serum sRAGE concentration >340ng/L 
(median: 3, IQR: 1–5; n=34; p=0.013). Asterisk 




Table 2. Correlation between serum soluble RAGE (receptor for advanced glycation end-products) and histologic 
lesions in dogs with chronic inflammatory enteropathy (n = 102) included in the study. 
Parameter correlated with serum sRAGE 
concentrations 
Spearman ρ P-value Pcorr-value 
Histologic lesions (composite score)  -0.15 0.136 0.136 
  Morphologic criteria (composite score) -0.13 0.198 0.396 
  Inflammatory criteria (composite score) -0.09 0.357 0.714 
Stomach 
   Morphologic criteria 0.01 0.973 ns 
      Fundus  





§ Gastric pit epithelial injury -0.13 0.249 0.747 
§ Mucosal fibrosis -0.04 0.722 ns 
      Antrum 
§ Surface epithelial injury -0.03 0.770 ns 
§ Gastric pit epithelial injury  0.15 0.162 0.486 
§ Mucosal fibrosis -0.01 0.903 ns 
   Inflammatory criteria -0.12 0.269 0.269 
      Fundus 
§ Intraepithelial lymphocytes -0.07 0.509 ns 
§ Lamina propria LPC -0.13 0.228 ns 
§ Lamina propria eosinophils  0.14 0.204 ns 
§ Lamina propria neutrophils N/A N/A N/A 
§ Lamina propria MΦ  0.07 0.486 ns 
§ Lymphoid follicular hyperplasia -0.01 0.978 ns 
      Antrum 
§ Intraepithelial lymphocytes -0.10 0.359 ns 
§ Lamina propria LPC -0.22 0.038 0.228 
§ Lamina propria eosinophils -0.03 0.789 ns 
§ Lamina propria neutrophils  0.14 0.209 ns 
§ Lamina propria MΦ -0.03 0.812 ns 
§ Lymphoid follicular hyperplasia -0.10 0.369 ns 
Duodenum (composite score) -0.19 0.070 0.210 
    Morphologic criteria (sum) -0.14 0.189 0.378 
§ Villus stunting -0.10 0.354 ns 
§ Epithelial injury  0.03 0.759 ns 
§ Crypt distension -0.23 0.027 0.135 
§ Lacteal dilatation -0.11 0.310 ns 
§ Mucosal fibrosis  0.07 0.512 ns 
    Inflammatory criteria (sum) -0.14 0.189 0.378 
§ Intraepithelial lymphocytes -0.05 0.602 ns 
§ Lamina propria LPC -0.25 0.017 0.085 
§ Lamina propria eosinophils  0.01 0.902 ns 
§ Lamina propria neutrophils -0.21 0.044 0.176 
§ Lamina propria MΦ  0.12 0.256 0.768 
Ileum (composite score)  0.11 0.629 ns 
    Morphologic criteria (sum)  0.09 0.670 ns 
§ Villus stunting  0.13 0.545 ns 
§ Epithelial injury  0.20 0.346 ns 
§ Crypt distension  0.24 0.254 ns 
§ Lacteal dilatation -0.25 0.238 ns 
§ Mucosal fibrosis N/A N/A N/A 
    Inflammatory criteria (sum)  0.10 0.645 ns 
§ Intraepithelial lymphocytes  0.04 0.843 ns 
§ Lamina propria LPC  0.17 0.417 ns 
§ Lamina propria eosinophils  0.06 0.781 ns 





§ Lamina propria MΦ  0.20 0.341 ns 
Colon (composite score) -0.07 0.692 ns 
    Morphologic criteria (sum) -0.20 0.262 0.524 
§ Epithelial injury -0.11 0.550 ns 
§ Crypt distension -0.23 0.177 0.708 
§ Change in goblet cells  0.04 0.833 ns 
§ Mucosal fibrosis -0.11 0.542 ns 
    Inflammatory criteria (sum)  0.08 0.649 ns 
§ Intraepithelial lymphocytes -0.14 0.418 ns 
§ Lamina propria LPC  0.08 0.668 ns 
§ Lamina propria eosinophils  0.15 0.389 ns 
§ Lamina propria neutrophils -0.06 0.731 ns 
§ Lamina propria MΦ  0.02 0.910 ns 
LPC = lymphocytes/plasma cells; MΦ = macrophages; N/A = not applicable; ns = not significant; Pcorr = Holm-




Figure 4. Association of serum sRAGE and 
S100A12 concentrations in dogs with 
chronic inflammatory enteropathy (CIE; 
n=93). Dogs with an undetectable serum 
sRAGE concentration (≤ 52 ng/L; n = 10) had 
numerically higher serum S100A12 concen-
trations (median: 316 µg/L, interquartile 
range [IQR]: 197–447µg/L) compared to 
dogs with detectable serum sRAGE concen-
trations (median: 207µg/L, IQR: 127–
320µg/L; n=83) but there was no significant 
difference between the groups (p = 0.081). 
 
 
Figure 5. Association of hypoalbuminemia 
and serum sRAGE concentrations in dogs 
with chronic inflammatory enteropathy 
(CIE). Dogs with more severe hypoalbu-
minemia (n=15) had numerically lower serum 
sRAGE concentrations (moderate hypoalbu-
minemia—median: 252ng/L, interquartile 
range [IQR]: 103–381 ng/L; severe hypoalbu-
minemia—median: 215 ng/L, IQR: 70–
286ng/L) than dogs with normoalbuminemia 
(median: 297ng/L, IQR: 137–499ng/L) or 
mild hypoalbuminemia (median: 285 ng/L, 
IQR: 212–782 ng/L; n = 86), but there were 
no significant differences among those groups 






Association of serum sRAGE concentrations with response to treatment 
Serum sRAGE concentrations were lower in dogs diagnosed with IRE (n = 15; median: 248 
ng/L, IQR: 52–554 ng/L) com- pared to dogs with FRE (n = 5; median: 415 ng/L, IQR: 217– 
565 ng/L), but the difference was not statistically significant (p = 0.189; Table 3). 
Table 3. Characteristics of dogs with food-responsive enteropathy (FRE) or immunosuppressant-responsive/-re-
fractory enteropathy (IRE) with available case outcomes (n = 20). 
Group characteristic FRE IRE 
Total number 5 15 
 
Age (y), median (IQR) 8 (1–10) 8 (7–10) 
Sex, male/female 3/2 8/7 
Body weight (kg), median (IQR) 19.4 (9.1–37.6)  12.4 (4.4–25.0)  
Follow-up time (mo), median (IQR) 15 (6-18) 9 (4-12) 
 
CCECAI score, median (IQR) 6 (3–8) 9 (5–10) 
Clinical disease severity, n (%) 
Mild* 2 (40%) 4 (27%) 
Moderate† 2 (40%) 2 (13%) 
Severe‡ 1 (20%) 7 (47%) 
Very severe§ 0 2 (13%) 
 
Serum sRAGE (ng/L), median (IQR) 415 (217–565) 248 (52–554) 
   >340 ng/L, n (%) 3 (60%) 4 (27%) 
   ≤340 ng/L, n (%) 2 (40%) 11 (73%) 
      52–340 ng/L, n (%)   2 (40%)   7 (47%) 
      ≤52 ng/L, n (%)   0 (0%)   4 (27%) 
Serum albumin (g/L), median (IQR) 31 (30–35) 22 (17–29) 
Hypoalbuminemia, n (%) 0 6 (40%) 
Mild¦ – 4 (27%) 
Moderate# – 0 
Severe¶ – 2 (13%) 
Serum cobalamin (ng/L), median (IQR) 367 (293–872) 226 (178–331) 
Hypocobalaminemia, n (%)** 0 8 (53%) 
Serum folate (µg/L), median (IQR) 15.1 (12.7–21.2) 15.8 (9.4–19.7) 
Hypofolatemia, n (%) 0 3 (20%) 
Hyperfolatemia, n (%) 0 1 (7%) 
Serum CRP (mg/L), median (IQR) 1.4 (0.6–2.8) 14.3 (8.5–37.8)†† 
Fecal calprotectin (µg/g), median (IQR) 0.9 (0.5–1.6) 1.6 (0.8–17.7) 
Serum calprotectin (mg/L), median (IQR) 6.1 (2.6–9.6)‡‡ 9.3 (4.8–11.1)§§ 
Fecal S100A12 (ng/g), median (IQR) 72 (35–193) 205 (59–1087) 
Serum S100A12 (µg/L), median (IQR) 93 (40–233) 232 (152–393)¦¦ 










CCECAI = canine chronic enteropathy clinical disease activity index; CRP = C-reactive protein; FRE = food-respon-
sive enteropathy; IQR = interquartile range; IRE = immunosuppressant-responsive/-refractory enteropathy. *CCECAI 
score of 4–5, †CCECAI score of 6–8, ‡CCECAI score of 9–11, §CCECAI score of ≥12; ¦defined as a serum albumin 
concentration 15–20 g/L; #defined as a serum albumin concentration 12–14.9 g/L; ¶defined as a serum albumin con-
centration <12 g/L; **defined as a serum cobalamin concentration <300 ng/L; ††available from 14 dogs diagnosed 
with IRE; ‡‡available from 2 dogs with FRE; §§available from 5 dogs with IRE; ¦¦available from 11 dogs with IRE; 
##available from 12 dogs with IRE. 
 
Discussion 
The weak correlation between the severity of histologic lesions in the proximal gastrointestinal 
tract (i.e., duodenal lymphoplasmacytic and neutrophilic infiltrate, duodenal crypt dilation, and 
lymphoplasmacytic infiltration in the gastric antrum)—which did not remain significant after 
correction for multiple comparisons—together with the decrease in serum sRAGE concentra-
tions might suggest a dysregulation of the sRAGE/RAGE axis in canine CIE, suggesting that 
sRAGE and also intestinal RAGE expression is of interest to further study the pathology of 
CIE. The serum sRAGE decoy receptor deficiency might signal a perturbation in membrane-
bound RAGE signaling (i.e., an increased activation of the receptor causing proinflammatory 
intracellular signaling), either as a cause or consequence of the disease. This finding is also 
interesting, considering the potential worse prognosis of CIE dogs with more severe mucosal 
lesions in the duodenum1 and our previous finding that serum sRAGE concentrations subse-
quently increased only in those dogs with a complete response to treatment.15 These findings 
differ slightly from the results of our previous pilot study in which no correlation was seen 
between histologic lesions and serum sRAGE concentrations,15 but a limitation of that study 
was the small sample size. Also, endoscopic lesion scores were not obtained in our current 
study and could not be evaluated for a possible association with serum sRAGE concentrations. 
Our results agree with the inverse relationship between serum sRAGE concentrations and the 
severity of histologic lesions in patients with Crohn disease,7 although the primary disease lo-
cation in human Crohn disease differs from the distribution of lesions in dogs with CIE.5 Intes-
tinal expression of RAGE at the protein level was also shown to correlate with inflammatory 
lesions in human patients with IBD.31 Although histologic lesion severity was not evaluated, 
another study found that plasma sRAGE concentrations correlated with the severity of endo-
scopic lesions in patients with IBD.25 Whether genetic defects in the RAGE gene also contribute 
to a dysregulation in the sRAGE/RAGE axis33 in canine CIE is unknown and requires further 
investigation. 
In contrast to the severity of histologic lesions, the severity of clinical signs was not correlated 
with serum sRAGE concentrations in our study. This finding is consistent with the lack of cor-
relation between RAGE positivity and clinical disease activity index in human IBD patients, 
but serum sRAGE concentrations were not evaluated in that study.6 However, our findings are 






tivity and serum sRAGE concentrations in Crohn disease and ulcerative colitis patients.7 Simi-
lar to our results, a study6 also found no correlation with prior treatment or disease duration in 
people. 
Serum sRAGE concentrations were not correlated with any of the serum or fecal biomarkers of 
inflammation or protein loss that we evaluated, and only a trend of an association was seen for 
serum S100A12 concentrations. This could be explained by spatial and/or temporal differences 
in the expression of these molecules and also by the recognition of various 3-dimensional mo-
lecular structures by RAGE, which includes exogenous ligands and also endogenous molecules 
such as the S100/calgranulin proteins.3 Consistent with the results of our study, a correlation of 
serum sRAGE with fecal calprotectin or serum S100A12 concentrations was also not found in 
patients with Crohn disease, whereas an inverse correlation existed between serum sRAGE and 
fecal calprotectin concentration in patients with ulcerative colitis.7 Lack of a relationship be-
tween serum sRAGE and CRP concentrations in canine CIE also agrees with the results in 
patients with ulcerative colitis7 but differs from findings in patients with Crohn disease.7,25 
Thus, further evaluation of the ligand-RAGE pathways and the sRAGE/RAGE axis is war-
ranted. 
We acknowledge that our study had some limitations. First, the possibility of a concurrent dis-
ease process (e.g., chronic or subclinical pancreatitis) being present and affecting serum sRAGE 
concentrations in some dogs can- not be excluded entirely. Also, fecal viral screening tests are 
not included in the standard diagnostic work-up of patients with a suspicion of CIE.2,8,10,24 Thus, 
the possibility of a (concurrent) infectious (e.g., chronic viral or occult parasitic) gastrointesti-
nal disease cannot be entirely excluded in the dogs in our study. Although we included many 
dogs with CIE, the smaller size of the subgroups of dogs with FRE and dogs with SRE or IRE 
presents another limitation. Thus, long-term outcome and prognosis could not be evaluated for 
most dogs in our study. Third, a limited number of dogs were included in the analysis of some 
markers in serum and fecal samples. Thus, the possibility of a type II error for finding no sig-
nificant differences or associations cannot be excluded. Further, histopathology of gastrointes-
tinal tissue biopsies was evaluated by 9 different board-certified pathologists (albeit with spe-
cial expertise in canine gastrointestinal pathology), which might be associated with a high in-
terobserver variation despite the use of standardized criteria.24 Last, sRAGE concentrations in 
serum were analyzed after sample storage for up to 6 y. The stability of sRAGE in canine serum 
is unknown and could also affect the results of our study. 
Our study confirms our previous finding that serum sRAGE concentrations are significantly 
decreased in dogs with CIE. Our current study further suggests that serum sRAGE might be 
associated with the severity of histologic lesions. It remains to be determined whether the de-
crease detected in the systemic concentrations of this decoy receptor is a cause (decreased sys-
temic production contributing to the pathogenesis of canine CIE) or consequence (consumption 
in the context of inflammation) of CIE in these patients. With the hypothesis that the expression 
of full-length transmembrane RAGE in the intestinal epithelium correlates with the serum 
sRAGE level, further research is now needed to investigate the expression of the RAGE recep-
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Abstract: The pathogenesis of chronic inflammatory enteropathies (CIE) in dogs involves 
dysregulated innate immune responses. The receptor for advanced glycation end products 
(RAGE), a pattern recognition receptor, plays a role in chronic inflammation. Abrogation of 
proinflammatory RAGE signaling by ligand binding (e.g., S100/calgranulins) to soluble RAGE 
(sRAGE) might also be a novel therapeutic avenue. Serum sRAGE levels are decreased in ca-
nine CIE, but gastrointestinal tissue RAGE expression has not been investigated in dogs. Thus, 






Further, the potential binding of RAGE to canine S100/calgranulin ligands was investigated. 
Epithelial RAGE expression was quantified in gastrointestinal (gastric, duodenal, ileal, and co-
lonic) biopsies from 12 dogs with CIE and 9 healthy control dogs using confocal laser scanning 
microscopy. RAGE expression was compared between both groups of dogs and was tested for 
an association with patient characteristics, clinical variables, histologic lesion severity, and bi-
omarkers of extra-gastrointestinal disease, systemic or gastrointestinal inflammation, function, 
or protein loss. Statistical significance was set at p < 0.05. 
RAGE:S100/calgranulin binding was assessed by immunoassay and electrophoretic tech-
niques. RAGE expression was detected in all 59 biopsies from diseased and healthy control 
dogs evaluated. Epithelial RAGE expression in the duodenum and colon was significantly 
higher in dogs with CIE than in healthy controls (p < 0.04). Compared to healthy controls, 
RAGE expression in dogs with CIE also tended to be higher in the ileum but lower in the stom-
ach. A slight (statistically not significant) shift towards more basal intestinal epithelial RAGE 
expression was detected in CIE dogs. Serum sRAGE was proportional to epithelial RAGE ex-
pression in the duodenum (p < 0.04), and RAGE expression in the colon inversely correlated 
with biomarkers of protein loss in serum (both p < 0.04). Several histologic morphologic and 
inflammatory lesion criteria and markers of inflammation (serum C-reactive protein and fecal 
calprotectin concentration) were related to epithelial RAGE expression in the duodenum, ileum, 
and/or colon. In vitro canine RAGE:S100A12 binding appeared more pronounced than 
RAGE:S100A8/A9 binding. This study showed a dysregulation of epithelial RAGE expression 
along the gastrointestinal tract in dogs with CIE. Compensatory regulations in the 
sRAGE/RAGE axis are an alternative explanation for these findings. The results suggest that 
RAGE signaling plays a role in dogs with CIE, but higher anti-inflammatory decoy receptor 
sRAGE levels paralleled RAGE overexpression. Canine S100/calgranulins were demonstrated 
to be ligands for RAGE. 
 
Keywords: Canine; immunofluorescence; inflammatory bowel disease; innate immunity; pat-
tern recognition receptor; receptor for advanced glycation end products. 
 
1. Introduction 
Chronic inflammatory enteropathies (CIE) are a group of diseases in dogs that are further clas-
sified based on the response to treatment as either food-responsive enteropathy (FRE; if patients 
show significant improvement or resolution of their clinical signs following a dietary trial with 
an elimination diet) or steroid- and/or immunosuppressant-responsive enteropathy (SRE/IRE; 
if dogs need to be treated with corticosteroids such as prednisolone or budesonide, and/or other 
immunosuppressive medication such as cyclosporine, azathioprine, or chlorambucil) (Allen-
spach, 2016; Dandrieux, 2016). Finally, dogs with a CIE not responding to steroid- or immu-
nosuppressant treatment are classified as having a steroid- and/or immunosuppressant-refrac-
tory enteropathy (NRE) (Allenspach, 2016; Dandrieux, 2016). Histologically, there appears to 
be no clear distinction between these three groups of dogs with CIE (Day et al., 2008; Washabau 
et al., 2010), and all CIE subclasses require the exclusion of other underlying causes for the 






Thus, the clinical work-up for dogs suspected to have CIE – particularly those dogs with 
SRE/IRE – aims for a diagnosis of exclusion, and arriving at this diagnosis can be challenging. 
The existence of a previously proposed fourth subgroup of CIE, antibiotic-responsive enterop-
athy (ARE; in which affected dogs show a marked and lasting improvement in their clinical 
signs following antibiotic administration), is currently being questioned (Erdmann and Heil-
mann, 2017; Cerquetella et al., 2020). The etiology of canine CIE appears to be complex (Dan-
drieux, 2016; Erdmann and Heilmann, 2017). Recent studies suggest that dysregulated signal-
ing mechanisms within the innate immune system and its cross-talk with other acquired immune 
responses play a relevant role in the pathogenesis of canine CIE (Jergens & Simpson, 2012; 
Heilmann & Allenspach, 2017). Pattern recognition receptors (PRR) play an important part in 
the signaling mechanisms of the innate immune response. These PRRs recognize exogenous 
pathogen-associated molecular pattern (PAMP) molecules as well as endogenous damage-as-
sociated molecular pattern (DAMP) molecules and regulate innate immune responses (Heil-
mann and Allenspach, 2017). The hypothesis that defects and dysregulations in innate immune 
PRRs contribute to the complex pathogenesis of CIEs in dogs has become an important focus 
of research in recent years (Heilmann and Allenspach, 2017). 
 
The receptor for advanced glycation end products (RAGE) is a PRR of the innate immune sys-
tem (Hofmann et al., 1999) and plays a central role in the pathogenesis of chronic inflammatory 
diseases, including gastrointestinal inflammation, in humans (Hofmann et al., 1999; Bierhaus 
et al., 2005; Ciccocioppo et al., 2013; Body-Malapel et al., 2019; Bramhall et al., 2020). Fol-
lowing the detection and binding of DAMP molecules (such as the S100/calgranulin proteins), 
transmembrane RAGE can induce and even maintain an inflammatory cascade (Hofmann et 
al., 1999; Heilmann and Allenspach, 2017). The full-length (transmembrane) form of RAGE 
consists of 5 domains (Heilmann and Allenspach, 2017). In addition to the complete transmem-
brane receptor, there are several isoforms of this molecule, including the soluble forms of 
RAGE (sRAGE) from which the membrane and cytoplasmic part is missing or has been cleaved 
(Heilmann et al., 2014). sRAGE acts as a decoy receptor because it can bind to its ligands and 
abrogate the transmembrane RAGE-ligand interaction, thus contributing to a downregulation 
of the inflammatory cascade (Taguchi et al., 2000; Bierhaus et al., 2005; Maillard-Lefebvre et 
al., 2009; Bramhall et al., 2020). 
 
Previous analysis showed the highest level of RAGE expression in human tissues to be present 
in the lung (Schmidt et al., 2000). A recent study demonstrated that full-length RAGE is ex-
pressed in the small intestine as well as the colon in people and mice and that intestinal RAGE 
expression is upregulated in patients with chronic inflammatory conditions (Body- Malapel et 
al., 2018). Furthermore, this study suggests that interference with the sRAGE/RAGE axis is a 
potential avenue for developing of novel therapeutic targets (Body-Malapel et al., 2018). Two 
different functional allelic and genotypic polymorphisms of RAGE were associated with a di-
agnosis of inflammatory bowel disease (Crohn’s disease or ulcerative colitis) in humans (Cic-
cocioppo et al., 2019). These findings further suggest a role for RAGE in the regulation of 







There are currently 24 known variants of RAGE in dogs (Sterenczak et al., 2009; Heilmann & 
Allenspach, 2017). Expression of RAGE has been investigated in dogs with malignant lym-
phoma (Sterenczak et al., 2010) and dogs with histiocytic sarcoma showing that RAGE dysreg-
ulation is associated with the progression of histiocytic disorders (Sterenczak et al., 2011). A 
previous study in dogs showed that serum sRAGE concentrations are significantly lower in 
dogs with CIE than in healthy dogs, and sRAGE concentrations increased only in those dogs 
with CIE that showed complete clinical remission following the initiation of treatment (Heil-
mann et al., 2014). Serum sRAGE concentrations were associated with microscopic lesions in 
the duodenum in dogs with CIE, further suggesting that the sRAGE/RAGE axis is dysregulated 
in dogs with CIE (Cabrera-García et al., 2020). However, the gastrointestinal mucosal expres-
sion of RAGE in dogs with CIE and its association with serum sRAGE concentrations, as well 
as other disease markers, has not yet been investigated. 
 
We hypothesized that the RAGE receptor is overexpressed in the gastrointestinal mucosa of 
dogs diagnosed with CIE and that the increased cellular RAGE expression correlates with de-
creased serum sRAGE concentrations and the severity of the disease. We further hypothesized 
that canine S100/calgranulin proteins bind to sRAGE in vitro. Thus, the aims of this study were 
(i) to immunohistologically investigate and quantify mucosal RAGE expression along the dif-
ferent segments of the gastrointestinal tract (i.e., stomach, duodenum, ileum, and colon) and 
(ii) to evaluate the possibility of an association of gastrointestinal RAGE expression with serum 
sRAGE concentration, clinical and histological disease severity, and the concentrations of other 
biomarkers of gastrointestinal inflammation or protein loss. The secondary aim of this study 
was to assess the in vitro binding of canine sRAGE to the S100/calgranulin proteins. 
 
2. Materials and methods 
2.1. Ethics approval 
The enrollment of dogs with CIE into the study of several markers was approved by the Clinical 
Research Review Committee (CRRC approval #TAMU 2009-06, approved 01-15- 2009) and 
the Institutional Animal Care and Use Committee at Texas A&M University (IACUC approval 
#TAMU 2012-083, approved 05-22-2012). Owners were informed, and all samples were col-
lected following their written consent. 
2.2. Sampling population 
2.2.1. Dogs with CIE 
Tissue biopsies of the gastrointestinal tract (i.e., stomach, duodenum, ileum, and colon), whole 
blood, serum, urine, and fecal samples (from 3 consecutive days) were collected from 12 dogs 
recruited between May 2011 and October 2014 at the Gastrointestinal Laboratory and the Vet-
erinary Teaching Hospital at Texas A&M University (Table 1). Information about some of the 
dogs has previously been reported (Cabrera-García et al., 2020). Patients were included in the 
study if they showed clinical signs of chronic enteropathy (i.e., vomiting, diarrhea, and/or 






atypical hypoadrenocorticism, exocrine pancreatic insufficiency, or alimentary lymphoma) 
had been excluded, and no anti-inflammatory and/or immunosuppressive medication had been 
administered within at least 2 weeks prior to enrollment into the study. There were no re-
strictions on breed, age, diet, or other medications (e.g., proton pump inhibitors) or supplements 
(e.g., cyanocobalamin, probiotics) for inclusion in this study. 
Table 1. Clinical characteristics of the dogs with chronic inflammatory enteropathy (CIE; n = 12) and healthy 
control dogs (n = 9) included in the study (n = 21). 
Group characteristic CIE dogs Healthy dogs 
Total number 12 9 
 
Age in years, median (IQR) 5.3 (1.6–8.1) 8.4 (1.5–8.9) 
Sex, male/female 9/3 2/7 
Body weight in kg, median (IQR) 16.9 (10.3–26.7) 25.8 (20.1–26.4) 
Breed, n (%) 
Pure-bred dogs 11 (92%) 9 (100%) 
Mixed breed dogs 1 (8%) 0 
Disease duration in months, median (IQR) 4 (2–12) – 
Follow-up time in months, median (IQR) 13 (4–18) – 
CIE classification based on follow-up, n (%)† 
FRE 2 (67%) – 
SRE/IRE 1 (33%) – 
CCECAI score, median (IQR)* 6 (4–9) – 
Clinical disease severity, n (%)* 
Mild clinical disease (CCECAI score: 4–5) 4 (36%) – 
Moderate clinical disease (CCECAI score: 6–8) 4 (36%) – 
Severe clinical disease (CCECAI score: 9–11) 2 (19%) – 
Very severe clinical disease (CCECAI score: ≥12) 1 (9%) – 
CCECAI = canine chronic enteropathy clinical disease activity index; CIE = chronic inflammatory enteropa-
thy; FRE = food-responsive enteropathy; IQR = interquartile range; IRE = immunosuppressant-responsive/-
refractory enteropathy. *available from 11 dogs diagnosed with CIE; †available from 3 dogs diagnosed with 
CIE. 
 
The severity of clinical disease displayed by these dogs was assessed using an established clin-
ical scoring system (i.e., canine chronic enteropathy clinical activity index, CCECAI [Allen-
spach et al., 2007]). The individual clinical parameters included in the CCECAI (i.e., appetite, 
frequency of vomiting, stool consistency and frequency of defecation, weight loss, serum albu-
min concentration, peripheral edema or ascites, and pruritus) are graded from 0–3 (0: normal, 
1: slightly abnormal, 2: moderately abnormal, and 3: severely abnormal). The sum of these 
individual scores is interpreted as the cumulative CCECAI score, where a score of 0– 3 reflects 






clinical disease, a score of 9–11 severe clinical disease, and a score of ≥12 very severe clinical 
disease (Allenspach et al., 2007). 
 
In addition to a complete blood cell count and a serum biochemistry profile, serum concentra-
tions of specific canine pancreatic lipase (Spec cPL, a marker used for the diagnosis of pancre-
atitis), cobalamin and folate (markers of gastrointestinal function), and C-reactive protein 
(CRP), calprotectin, and S100A12 as markers of systemic inflammation were measured. Mark-
ers of gastrointestinal inflammation (i.e., fecal calprotectin and S100A12 concentrations) or 
protein loss (i.e., fecal and serum alpha1-proteinase inhibitor [a1PI] concentrations) were also 
determined. Serum sRAGE concentrations were measured by ELISA as previously described 
(Heilmann et al., 2014; Cabrera-García et al., 2020). 
 
Gastrointestinal tissue biopsies (endoscopic biopsies from 11 dogs, surgical biopsies from 1 
dog) were histopathologically evaluated by one of 6 board-certified pathologists using the cri-
teria of the World Small Animal Veterinary Association Gastrointestinal Standardization grad-
ing system (Day et al., 2008; Washabau et al., 2010). Individual structural and inflammatory 
lesions were graded as absent (score = 0), mild (score =1), moderate (score = 2), or severe 
(score = 3), and cumulative lesion scores were calculated as the sum of individual lesion scores 
of each segment of the gastrointestinal tract. 
2.2.2. Healthy controls 
Full-thickness gastrointestinal tissue biopsies (i.e., stomach, duodenum, ileum, and colon) were 
also obtained from 9 purpose-bred healthy Hound dogs (Table 1) that were euthanized for an 
unrelated project at the College of Veterinary Medicine and Biomedical Sciences at Texas 
A&M University (AUP approval #TAMU 2009-0123). To be included as a healthy control dog 
in this study, the dog could not have any clinical signs of gastrointestinal disease, receive any 
medication known to affect the gastrointestinal tract, and needed to be regularly vaccinated and 
dewormed. 
 
2.3. Quantitative evaluation of RAGE in gastrointestinal tissue biopsies 
2.3.1. Immunofluorescence staining protocol 
Tissue biopsy samples from canine stomach and intestines (i.e., duodenum, ileum, colon) as 
well as canine lung (a tissue with very high expression levels of RAGE in the naïve state 
[Schmidt et al., 2000]) as positive control tissue (all surplus material from unrelated necropsies) 
were fixed in formalin, paraffin-embedded, and cut at 5 µm-thickness, and served to establish 
and optimize the RAGE immunofluorescence staining protocol (Fig. 1). 
After deparaffination in xylol and a decreasing ethanol series, the tissues were permeabilized 
using 0.1% (v/v) Triton X-1001 in PBS. Antigen demasking was achieved by hot citric acid 
with 0.025% (v/v) Tween-20 (PBST) (approximately 95°C; 10 mM, pH 6.0). Endogenous pe-
roxidase was blocked with 3% (v/v) H2O2 for 1 h. Blocking of non-specific binding sites was 
achieved with 2.5% (v/v) bovine serum albumin in PBST for 1 h at room temperature (approx-






were tested for their suitability as a primary antibody for tissue RAGE staining, and antibody 
specificity was confirmed by Western blot (data not shown). Tissue sections 1:20 anti-recom-
binant canine RAGE), using a non-specific goat (a-armenian hamster) antibody (diluted at 
1:1500), served as a negative control. For all tissues, rabbit anti-goat IgG4 was used as second-
ary antibody at a 1:500 dilution and were then incubated overnight at 4°C with the primary 
antibody selected based on the anti-recombinant canine RAGE3 diluted at signal in Western 
blot analysis (polyclonal incubation period of 1 h at room temperature. A polyclonal horserad-
ish peroxidase-labeled goat anti-rabbit IgG5 was used as tertiary detection antibody. Following 
the removal of excess antibody, the sections were incubated with Alexa FluorTM488 nm tyra-
mide reagent6 for 5 min. Nuclei were counterstained with Hoechst 333427. The presence of 
tissue RAGE expression was analyzed in gastrointestinal and pulmonary tissue samples by 
screening the slides using a fluorescence microscope8 and the cellSens Dimension software9. 
 
2.3.2. Confocal laser scanning microscopic (CLSM) data acquisition and analysis 
For gastrointestinal tissues (stomach, duodenum, ileum, and colon), RAGE expression was 
quantitatively determined by measuring the fluorescence intensity applying photon counting 
(in voxels) on a confocal laser scanning microscope (CLSM).10 Alexa FluorTM488 was excited 
at 514 nm, and photon counting was performed using a hybrid detector (HyD)11 at an emission 
range of 550–603 nm and a 63×/1.30 Glyc objective12. CLSM was conducted following a two-
step protocol. First, an overview (tile scan at 600 Hz bidirectional, pinhole: 2 airy units [AU]) 
of the entire tissue section was created with a scan resolution of 256×256 pixels. The overview 
scan, allowing equal pre-illumination of the fluorescent tissue prior to photon counting, pro-
vided a virtual slide of the section. This scan served as the basis for selecting 4 regions (scan 
positions) in each gastrointestinal tissue (including up to 4 different biopsies for endoscopically 
collected tissues) that met the structural requirements (i.e., intact epithelial surface, proper ori-
entation of the tissue, distinction between villus and crypt area in the duodenum and ileum, and 
distinction between apical and basal portion of the epithelium in the duodenum, ileum, and 
colon) for further evaluation of tissue RAGE immunoreactivity (Fig. 2). 
 
2.3.2. Confocal laser scanning microscopic (CLSM) data acquisition and analysis 
For gastrointestinal tissues (stomach, duodenum, ileum, and colon), RAGE expression was 
quantitatively determined by measuring the fluorescence intensity applying photon counting 
(in voxels) on a confocal laser scanning microscope (CLSM).10 Alexa FluorTM 488 was excited 
at 514 nm, and photon counting was performed using a hybrid detector (HyD)11 at an emission 
range of 550–603 nm and a 63×/1.30 Glyc objective12. CLSM was conducted following a two-
step protocol. First, an overview (tile scan at 600 Hz bidirectional, pinhole: 2 airy units [AU]) 
of the entire tissue section was created with a scan resolution of 256×256 pixels. The overview 
scan, allowing equal pre-illumination of the fluorescent tissue prior to photon counting, pro-
vided a virtual slide of the section. This scan served as the basis for selecting 4 regions (scan 
positions) in each gastrointestinal tissue (including up to 4 different biopsies for endoscopically 
collected tissues) that met the structural requirements (i.e., intact epithelial surface, proper ori-






distinction between apical and basal portion of the epithelium in the duodenum, ileum, and 
colon) for further evaluation of tissue RAGE immunoreactivity (Fig. 2). 
 
Second, photon counting was applied at the previously selected scan positions using a resolu-
tion of 512×512 pixels at 200 Hz unidirectional (pinhole: 1 AU). The transmission value of the 
514 nm-laser line, once appropriately set using the saturation control within the counting mode 
of the HyD, was kept unchanged for all photon counting records of the study. To assure that 
intensity measurements were carried out at corresponding focus planes all over the tissue sec-
tion, a focus map (maximum intensity mode) of the tissue section was created prior to photon 




Fig. 1. Representative fluorescence images show the localization of RAGE expression in canine pulmonary (panels 
A-B) and duodenal (panels C-D) tissue biopsy sections. Canine RAGE is displayed in green (Alexa FluorTM 488), 
and nuclei are stained blue (Hoechst 33342). RAGE is expressed in several sections of the lung of a healthy dog 
(panel A; indicated by white arrows) and sections of the duodenum of a dog with chronic intestinal inflammation 
(CIE, panel C; indicated by white arrows). Negative controls for non-specific reactions are also shown (Alexa 
FluorTM 488; panels B and D), with the nuclei stained blue (Hoechst 33342). Staining for RAGE in gastrointestinal 
tissues was performed with an enhancement kit due to the weak expression of RAGE in these tissues in the naïve 
state. In contrast, RAGE expression in the lung (used as positive control tissue to demonstrate adequacy of the 
staining protocol) is very strong in the naïve state, yielding a strong signal for RAGE over the entire tissue. (For 
interpretation of the references to color in this figure legend, the reader is referred to the web version of this article). 
Photon counting images were analyzed using the Leica software LAS-X 3.4.213 A total number 
of 59 sections, each at four positions, were analyzed: 12 obtained from gastric, 14 from duode-
nal, 16 from ileal, and 17 from colonic tissues obtained from 12 dogs with CIE and from 9 
healthy dogs. In duodenal, ileal, and colonic tissue, photon counting related to epithelial Alexa 






10 regions of interest (ROI; each with an area of 3.14 µm2 or a 2-µm diameter). In addition, 
section-specific control measurements were obtained by positioning 10 ROI in the center of 
goblet cell secretion, a portion of the epithelium supposed to show no RAGE expression, and 
was used for normalization against this section-specific background staining. In gastric biop-
sies, photon counting was determined with 10 ROI each in the cellular (extranuclear) part of 
epithelial cells (any portion because apical and basal regions could not be reliably distin-
guished) and, as control, in adjacent subepithelial soft tissue (lamina propria). To ensure the 
standardized positioning of the ROI at the brightest spots within the epithelium and the darkest 
spots within the lamina propria, images were displayed as greyscale pictures. Then, the upper 
and lower histogram thresholds were modified for the highest photon counts (brightest pixel) 
to be displayed as red pixels and the lowest photon counts (darkest pixel) as blue pixels (Fig. 3 
and 4). 
The average photon counts obtained from the 10 apical epithelial ROI, the 10 basal epithelial 
ROI, and the 10 cellular ROI were each normalized against the average photon count within 
the control region by calculation of their ratios (i.e., normalized apical epithelial photon count 
= [average photon count of the 10 apical epithelial ROI/ average photon count of the 10 control 
ROI] and normalized basal epithelial photon count = [average photon count of the 10 basal 
epithelial ROI/ average photon count of the 10 control ROI]). The average of all normalized 
apical (AECn), basal (BECn), and, for the gastric localizations, cellular (CECn) epithelial photon 
counts and the ratio between AECn and BECn (AECn-to-BECn ratio, ABR) were then calcu-




Fig. 2. Quantitative evaluation of RAGE expression in gastrointestinal tissue biopsies. (A) Overview scan of a 
colonic tissue biopsy by confocal laser scanning microscopy (CLSM) where green staining areas reflect RAGE 
expression. (B) Example of a defined area (position, white square in panel A) for evaluating tissue RAGE expres-
sion in an endoscopic colonic biopsy from a dog. The colored circles are the regions of interest (ROI) with the 
high-est (purple and blue circles) or lowest (yellow circles) signal intensity and in which the expression of  RAGE 
was quantified (also indicated by colored arrows): the apical area of the epithelium (purple circles, one example 
indicated by the purple arrow), basal area of the epithelium (blue circles, one example indicated by the blue arrow), 






small areas of artificial staining of macrophages and erythrocytes (CLSM, original magnification 63×/1.3 Glyc 
objective). (For interpretation of the references to color in this figure legend, the reader is referred to the web 




Fig. 3. Quantitative evaluation of RAGE in proximal gastrointestinal tissue biopsies. Left panel: examples of de-
fined areas (positions) for evaluating gastric (panel A) and duodenal (panel B) tissue RAGE expression in endo-
scopic tissue biopsies from a dog. Right panel: magnified view of an area within that position (white squares in 
panels A and B). The colored circles reflect the regions of interest (ROI) in which the expression of RAGE was 
quantified: cellular (extranuclear, blue circles) and control region (lamina propria, yellow circles) in the stomach 
(panel A’); and the apical area of the epithelium (purple circles), basal area of the epithelium (blue circles), and 
the control region (yellow circles) in the duodenum (panel B’). Original images of the positions converted to 
grayscale; red pixels indicate the highest photon counts (brightest pixel) and blue pixels the lowest photon counts 
(darkest pixel) (CLSM, 63×/1.3 Glyc objective). (For interpretation of the references to colour in this figure legend, 









Fig. 4. Quantitative evaluation of RAGE in distal gastrointestinal tissue biopsies. Left panel: examples of defined 
areas (positions) for evaluating ileal (panel A) and colonic (panel B) tissue RAGE expression in endoscopic tissue 
biopsies from a dog diagnosed with CIE. Right panel: magnified view of an area within that position (white squares 
in panels A and B). The colored circles reflect the regions of interest (ROI) in which the expression of RAGE was 
quantified: the apical area of the epithelium (purple circles), basal area of the epithelium (blue circles), and the 
control region (yellow circles) (panels A’ and B’).  Original images of the positions converted to grayscale; red 
pixels indicate the highest photon counts (brightest pixel) and blue pixels the lowest photon counts (darkest pixel) 
(CLSM, 63×/1.3 Glyc objective). (For interpretation of the references to colour in this figure legend, the reader is 










2.4. Assessment of in vitro binding of RAGE to S100/calgranulin proteins 
2.4.1. Radiolabeling of purified canine S100/calgranulin proteins 
Labeling of canine S100A12 and calprotectin (S100A8/A9) with radioactive iodine (125I) was 
performed by the chloramine T method as previously described (Heilmann et al., 2008; Heil-
mann et al., 2011) with the modification of adding 1.0 µL Na125I (0.1 mCi at the time of pro-
duction) to 10 µg of purified protein followed by an incubation for 60 s. 125I-tagged protein 
was then separated from free 125I by size exclusion, and the 125I-tagged protein fractions were 
supplemented with CaCl2 (2.4 mM in the final solution). 
2.4.2. Canine RAGE:S100/calgranulin protein binding ELISA 
In 3 independent experiments, wells of a flat-bottom enhanced binding ELISA plate14 were 
coated with recombinant canine RAGE15 (2.5 µg/well), affinity-purified polyclonal anti-canine 
S100A12 (1.5 µg/well) or anti-canine S100A8/A9 antibody (1.5 µg/well; positive controls), or 
bovine serum albumin (BSA; negative controls) dissolved in 200 mM carbonate-bicarbonate 
(pH 9.4), and were incubated for 20 h at 4°C. Wells were then washed three times with 25 mM 
Tris/HCl, 150 mM NaCl, 0.05% (v/v) polyoxyethylene-20 sorbitan monolaurate, pH 8.0. Non-
specific binding sites were blocked with 25 mM Tris/HCl, 150 mM NaCl, 0.05% (v/v) polyox-
yethylene-20 sorbitan monolaurate, 10% (w/v) BSA, pH 8.0 for 1 h at 37°C. Wells were hen 
incubated with 1.1 µg of 125I-tagged canine S100A12 (5.6 µCi/well) or 125I-tagged canine 
S100A8/A9 (3.2 µCi/well) in 25 mM Tris/HCl, 150 mM NaCl, 0.05% (v/v) polyoxyethylene- 
20 sorbitan monolaurate, 0.5% (w/v) BSA, pH 8.0 supplemented with 2.4 mM CaCl2 and 15 
(or 150) µM ZnSO4 (assay buffer) for 2 h at 37°C, and were then washed as described (with the 
supernatant being separately collected). Bound or captured 125I-S100A12 or 125I-S100A8/A9 
was detected by an automated -counter16. 
2.4.3. Canine RAGE:S100/calgranulin protein native polyacrylamide gel electrophoresis 
(PAGE) 
Canine RAGE15 (2.1 µM; molecular mass: 42–50 kDa) and increasing molarities of purified 
canine S100A12 and canine S100A8/A9 protein (0, 4.2, 10.5, 21.0, 31.5, and 42.0 µM) in 2.4 
mM CaCl2 were incubated for 4 h at room temperature (approximately 23°C) followed by na-
tive PAGE in a discontinuous buffer system and a separating gel with a 7% acrylamide con-
centration. Electrophoresis (buffers supplemented with 2.4 mM CaCl2) was performed at a con-
stant voltage of 125 V for 120 min at approximately 23°C, followed by Coomassie brilliant 
blue staining17. Scanned images were analyzed using the Quantity One® software18. 
 
2.4.4. Canine RAGE:S100A12 size exclusion chromatography (SEC) 
Canine RAGE15 (15 µg) and purified canine S100A12 protein (100 µg) in 20 mM HEPES- 
NaOH (pH 8.0), 100 mM NaCl, 2.4 mM CaCl2, 15 µM ZnSO4 (running buffer) were incubated 
overnight at 4°C and were then applied to a calibrated sephacryl SEC column19 (marker pro-
teins: ribonuclease A, chymotrypsinogen A, ovalbumin, BSA, and blue dextran 2000) and 
equilibrated with 5 column volumes (VC) of running buffer at a flow rate of 0.5 ml/min at room 






from the column were analyzed by reducing sodium dodecyl sulfate (SDS)-PAGE in a vertical 
mini-gel format (10% Bis/Tris), where protein bands were visualized by staining with Coo-
massie brilliant blue. Scanned images were analyzed using the Quantity One® software18. 
2.5. Statistical analyses 
A statistical software package was used for all statistical analyses21. Continuous variables were 
first assessed for normality of their distribution and equality of the variances using a Shapiro-
Wilk W test and a Brown-Forsythe test, respectively. Summary statistics for continuous varia-
bles are reported as medians and ranges. Categorical data are presented as counts (n) and per-
centages. 
A non-parametric Wilcoxon rank-sum test was used to compare the degree of gastric, duodenal, 
ileal, and colonic RAGE expression (AECn, BECn, CECn, and ABR) between dogs with CIE 
and healthy control dogs. A non-parametric Spearman rank correlation coefficient rho (r ) was 
calculated to test the possibility of a correlation between tissue RAGE expression (AECn, BECn, 
CECn, and ABR) and patient characteristics (age, body weight), clinical variables (CCECAI 
score, disease location), biomarkers of concurrent disease (Spec cPL), systemic inflammation 
(CRP, serum calprotectin, and S100A12), and gastrointestinal function (serum cobalamin and 
folate), inflammation (fecal calprotectin and S100A12), or protein loss (fecal and serum 1PI), 
and the severity of histological lesions in the stomach, duodenum, ileum, and colon. The Spear-
man was interpreted as indicating a very strong (0.8–1.0), strong (0.6–0.8), moderate (0.4–0.6), 
weak (0.2–0.4), or very weak (0–0.2) correlation. Statistical significance was set at p < 0.05. 
 
3. Results 
3.1. Study population 
A total of 21 dogs were included in the study: 12 dogs diagnosed with CIE and 9 healthy control 
dogs (Table 1). There were no differences in age (p = 0.5937) or body weight (p = 0.1627) 
between the two groups of dogs, but significantly more male dogs were present in the group of 
dogs with CIE (75%) compared to the healthy control group (22%, p = 0.0140) (Table 1). The 
CCECAI scores in dogs with CIE ranged from indicating mild to very severe clinical disease, 
with a median CCECAI score of 6 (moderate clinical disease activity) (Table 1). In the group 
of dogs with CIE, 3 dogs (25%) received antisecretory treatment (antihistamine and/or proton 
pump inhibitor) at the time of study enrollment and tissue sample collection; 3 dogs (25%) were 
given a probiotic and 3 dogs (25%) antimicrobials (metronidazole and/or tylosin). 
3.2. Gastrointestinal tissue RAGE expression 
3.2.1. RAGE expression along the gastrointestinal tract in healthy dogs and dogs with CIE 
Immunofluorescence staining of gastrointestinal tissue biopsies indicated that RAGE is ex-
pressed in the epithelium of the stomach, duodenum, ileum, and colon of all healthy dogs and 
dogs with CIE (Fig. 3 and 4, Table 2). Immunofluorescence analysis by CLSM showed a strong 






0.001), duodenum (r = 0.75, p = 0.0022), and colon (r = 0.67, p = 0.0030). These correlations 
remained for the ileum (r = 0.86, p = 0.0065) and colon (r = 0.73, p = 0.0158) in the group of 
dogs with CIE. In contrast, in healthy dogs, apical and basal epithelial RAGE expression were 
only correlated in the duodenum (r = 0.89, p = 0.0068). Among the different segments, there 
was a strong correlation between the basal compartments of the duodenum and colon (r = 0.83, 
p = 0.0017). 
 
Comparative immunofluorescence analysis showed a significantly higher epithelial RAGE ex-
pression in the duodenum and colon in dogs with CIE than in healthy dogs (Table 2). Compared 
to healthy controls, epithelial RAGE expression in dogs with CIE was numerically higher in 
the ileum but lower in the stomach. However, neither of these differences reached statistical 
significance (Table 2). A minimal shift towards more basal than apical epithelial RAGE ex-
pression (i.e., an increased ABR) was detected in the duodenum, ileum, and colon of dogs with 
CIE; but this was not statistically significant in any of these gastrointestinal segments. 
 
Table 2. Comparison of gastrointestinal tissue RAGE expression in dogs with CIE (n = 12) and healthy control 
dogs (n = 9) included in the study.  
Parameter CIE Healthy p-value 
Stomach 
  CECn, median (IQR) 5.36 (3.06–6.83) 7.33 (5.19–8.81) 0.1439 
    Number of biopsies 5 7  – 
Duodenum 
  AECn, median (IQR) 10.36 (8.14–15.20) 6.75 (4.70–8.67) 0.0152 
  BECn, median (IQR) 12.72 (10.93–14.32) 6.09 (4.51–7.73) 0.0033 
  ABR, median (IQR) 1.02 (0.62–1.11) 1.15 (1.02–1.17) 0.2502 
    Number of biopsies 7 7  – 
Ileum 
  AECn, median (IQR) 13.00 (8.93–16.95) 11.66 (6.71–20.98) 0.8748 
  BECn, median (IQR) 12.30 (8.02–19.34) 12.21 (7.08–17.58) 0.7929 
  ABR, median (IQR) 1.04 (0.82–1.13) 1.08 (0.91–1.17) 0.7929 
    Number of biopsies 8 8  – 
Colon 
  AECn, median (IQR) 10.24 (8.18–16.42) 6.32 (5.90–7.17) 0.0029 
  BECn, median (IQR) 11.64 (7.86–27.82) 7.65 (5.63–9.17) 0.0359 
  ABR, median (IQR) 0.94 (0.62–1.16) 0.98 (0.69–1.12) 0.9611 
    Number of biopsies 10 7  – 
CECn = normalized cellular epithelial photon counts; AECn = normalized apical epithelial photon counts; 
BECn = normalized basal epithelial photon counts; ABR = ratio between AECn and BECn. P-values in 
bold font indicate significance at p < 0.05. 
 
3.2.2. Correlation of gastrointestinal tissue RAGE expression with serum sRAGE levels 
Serum sRAGE concentrations ranged from 52–804 ng/L (median: 311 ng/L) in the group of 






ng/L, the previously determined cut-off concentration that best separated dogs with CIE from 
healthy controls (median: 448 ng/L, interquartile range: 326–536 ng/L [Heilmann et al., 2014]). 
Serum sRAGE concentrations were strongly correlated with the degree of apical epithelial 
RAGE expression in the duodenum (r = 0.79, p = 0.0362) (Table 4) but not with the expression 
of tissue RAGE or compartmental shift (ABR) in any of the other gastrointestinal segments 
evaluated in this study. 
Table 3. Clinicopathological and histological data for the dogs with CIE (n = 12) included in the study. 
Parameter Value 
Serum sRAGE concentration in ng/L, median (IQR) 311 (159–490) 
sRAGE concentration >340 ng/L, n (%) 5 (42%) 
sRAGE concentration ≤340 ng/L, n (%) 7 (58%) 
   sRAGE concentration 52–340 ng/L, n (%) 6 (50%) 
   sRAGE concentration ≤52 ng/L, n (%) 1 (8%) 
Serum CRP concentration in mg/L, median (IQR) 5.9 (0.9–15.4) 
Fecal calprotectin concentration in µg/g, median (IQR)* 1.5 (0.6–23.4) 
Serum calprotectin concentration in mg/L, median (IQR)† 8.2 (6.1–10.9) 
Fecal S100A12 concentration in ng/g, median (IQR)* 94 (33–2601) 
Serum S100A12 concentration in µg/L, median (IQR) 261 (196–440) 
Fecal α1PI concentration in µg/g, median (IQR)‡ 10.5 (5.1–36.3) 
Serum α1PI concentration in mg/L, median (IQR) 1485 (1303–1609) 
Serum albumin concentration in g/L, median (IQR) 28 (24–31) 
Hypoalbuminemia, n (%) 1 (8%) 
Mild hypoalbuminemia§ 1 (8%) 
Moderate hypoalbuminemia¦ 0 (0%) 
Severe hypoalbuminemia# 0 (0%) 
Serum total calcium concentration in md/dL, median (IQR) 9.6 (9.1–10.7) 
Serum cobalamin concentration in ng/L, median (IQR) 423 (299–782) 
Hypocobalaminemia¶, n (%) 2 (17%) 
Serum folate concentration in µg/L, median (IQR) 10.7 (8.9–20.1) 
Hypofolatemia**, n (%)   2 (17%) 
Hyperfolatemia††, n (%) 1 (8%) 
Serum Spec cPL concentration in µg/L, median (IQR) 43 (30–79) 
Serum gastrin concentration in µg/L, median (IQR) 13.0 (10.0–37.3) 
Histologic lesion score, median (IQR)  
Stomach 1 (1–2) 
Duodenum 1.5 (1–2) 
Ileum‡ 2 (1–2) 
Colon  1 (1–2) 
Overall lesion score 2 (1–2) 
CRP = C-reactive protein; IQR = interquartile range; Spec cPL = specific canine pancreatic lipase. 
*available from 8 dogs; †available from 6 dogs; ‡available from 11 dogs; §defined as a serum albumin 
concentration 15–20 g/L; ¦defined as a serum albumin concentration 12–14.9 g/L; #defined as a serum 
albumin concentration <12 g/L; ¶defined as a serum cobalamin concentration <300 ng/L; **defined as 








3.2.3. Correlation of gastrointestinal tissue RAGE expression with patient characteristics, 
clinical variables, and histopathologic lesions 
Gastrointestinal RAGE expression was not associated with the dogs’ age, body weight, disease 
duration, or CCEAI scores (Table 4). Histologic lesion scores ranged from 0 (no abnormalities) 
to 3 (severe lesions), with a median overall histologic lesion score indicating moderate histo-
logic changes (Table 3). Segmental tissue RAGE expression was strongly correlated with the 
degree of villus stunting (r = 0.76, p = 0.0487) and crypt dilation/distortion (r = 0.78, p = 
0.0399) in the basal compartment of the duodenum. The degree of eosinophilic infiltration (r 
= -0.80, p = 0.0319) and the overall (r = -0.94, p = 0.0048) and segmental histologic score (r 
= -0.78, p = 0.0399) were also strongly but inversely correlated with the epithelial RAGE ex-
pression in the apical compartment of the duodenum (Table 4). The compartmental shift (ABR) 
of epithelial RAGE expression in the ileum was strongly associated with the degree of neutro-
philic infiltration (r = 0.76, p = 0.0300), in the duodenum was inversely correlated with the 
severity of histologic lesions in that segment (r = -0.84, p = 0.0189), and in the colon it was 
inversely correlated with the degree of colonic intraepithelial lymphocyte infiltration (r = -0.70, 
p = 0.0240) and the overall inflammatory criteria (r = -0.73, p = 0.0166). Basal epithelial RAGE 
expression in the colon was related to the overall inflammatory score (r = 0.71, p = 0.0227). 
 
Table 4. Correlation (Spearman r) between gastrointestinal tissue RAGE expression and histological, clinical, 
and clinicopathological variables in dogs with CIE (n = 12). 
Parameter correlated 
with 
Stomach Duodenum Ileum Colon 
CECn AECn BECn ABR AECn BECn ABR AECn BECn ABR 
Histologic lesions (composite score)    0.30 -0.94 -0.09 -0.77  0.57  0.29  0.41  0.41  0.58 -0.47 
  Morphologic criteria (composite score)  0.40 -0.71  0.26 -0.66  0.60  0.44  0.12  0.38  0.28 -0.17 
  Inflammatory criteria (composite score) -0.20 -0.77 -0.37 -0.43  0.14 -0.05  0.45  0.34  0.71 -0.73 
 
 
Stomach Duodenum Ileum Colon 
Segment composite score  0.11 -0.78  0.30 -0.84  0.61  0.62 -0.17  0.12  0.39 -0.43 
   Morphologic criteria -0.35 -0.36  0.62 -0.49  0.10 -0.08  0.45  0.01  0.00  0.01 
§ Surface epithelial injury  n/a -0.63 -0.32 -0.16 -0.08 -0.25  0.41  0.00 -0.17  0.35 
§ Gastric pit epithelial injury  n/a    
§ Villus stunting  -0.09  0.76 -0.54 -0.08 -0.25  0.41  
§ Crypt dilation/distortion -0.54  0.78 -0.72  0.17  0.03  0.35 -0.28 -0.22  0.10 
§ Lacteal dilatation  0.23  0.14  0.13  n/a  n/a  n/a  
§ Change in goblet cells    0.12  0.16 -0.16 
§ Mucosal fibrosis -0.35  n/a  n/a  n/a  n/a  n/a  n/a  0.53  0.42 -0.23 
   Inflammatory criteria  0.63 -0.73  0.09 -0.46  0.01 -0.10  0.32  0.18  0.52 -0.54 
§ Intraepithelial lymphocytes  0.00 -0.66  0.22 -0.44  0.06  0.17 -0.17  0.24  0.51 -0.70 
§ Lamina propria LPC -0.31 -0.47  0.00 -0.19 -0.50 -0.32  0.06  0.45  0.43 -0.20 
§ Lamina propria eosinophils  0.21 -0.80  0.06 -0.60  0.65  0.34  0.18 -0.27  0.27 -0.51 
§ Lamina propria neutrophils  n/a -0.61  0.20 -0.41 -0.25 -0.50  0.76  n/a  n/a  n/a 
§ Lamina propria MΦ  n/a  n/a  n/a  n/a -0.08 -0.25  0.41  0.41  0.17  0.06 






§ Lymphoid follicular hyper-
plasia 
   
 Age   0.10 -0.07 -0.15 -0.15  0.12 -0.01  0.07  0.19 -0.10  0.14 
 Body weight -0.04 -0.32 -0.38  0.18 -0.37 -0.32  0.10 -0.07 -0.07 -0.06 
 Disease duration -0.40  0.00 -0.02  0.25 -0.41 -0.33  0.25  0.20 -0.19  0.07 
 CCECAI score  0.32 -0.44 -0.38 -0.44  0.36  0.18  0.31 -0.01 -0.14  0.22 
           
 Serum sRAGE concentration  0.00  0.79  0.21  0.39 -0.21 -0.19 -0.12 -0.10  0.30 -0.44 
 Serum CRP concentration  0.10 -0.29  0.29 -0.29  0.05 -0.26  0.71  0.52  0.10  0.07 
 Fecal calprotectin concentration -0.20  0.09  0.14  0.26 -0.55 -0.43  0.14  0.43  0.89 -1.00 
 Serum calprotectin concentration  0.50 -0.40 -0.40  0.20 -0.26  0.09 -0.14 -0.30 -0.30 -0.30 
 Fecal S100A12 concentration -0.10  0.32  0.11  0.43 -0.60 -0.31 -0.31  0.49  0.71 -0.66 
 Serum S100A12 concentration  0.00  0.32  0.46  0.21 -0.41 -0.02 -0.33 -0.10 -0.35  0.21 
 Fecal α1PI concentration -0.10  0.32  0.36  0.21 -0.48 -0.10 -0.29  0.43 -0.12  0.25 
 Serum α1PI concentration -0.10  0.46 -0.36  0.50 -0.31 -0.07 -0.48 -0.72 -0.53  0.06 
 Serum albumin concentration -0.30  0.00 -0.49  0.25 -0.08  0.08 -0.43 -0.64 -0.21 -0.15 
           
 Serum total calcium concentration -0.67  0.31 -0.58  0.67 -0.32 -0.20 -0.32 -0.32  0.31 -0.58 
 Serum cobalamin concentration  0.00 -0.68  0.14 -0.68  0.45  0.19  0.24 -0.06  0.48 -0.62 
 Serum folate concentration -0.30  0.25 -0.50  0.50 -0.50 -0.36 -0.12 -0.33 -0.26  0.22 
 Serum Spec cPL concentration  0.90 -0.18  0.20 -0.54  0.50  0.47 -0.10  0.10 -0.13  0.34 
 Serum gastrin concentration -0.67  0.19 -0.07  0.33 -0.58 -0.44 -0.07 -0.12 -0.17  0.01 
 
α1PI = alpha1-proteinase inhibitor; ABR = ratio between AECn and BECn; AECn = normalized apical epithelial photon 
counts; BECn = normalized basal epithelial photon counts; CCECAI = canine chronic enteropathy clinical disease 
activity index; CECn = normalized extranuclear (cytosolic) epithelial photon counts; LPC = lymphocytes/plasma 
cells; MΦ = macrophages; n/a = not applicable; Spec cPL = specific canine pancreatic lipase. Spearman r in bold 
font with green background indicate significance at p < 0.05. 
 
3.2.4. Correlation between gastrointestinal tissue RAGE expression and other biomarkers 
RAGE expression in the basal segment of the colon was very strongly associated with fecal 
calprotectin concentrations (r = 0.89, p = 0.0188), and in the apical segment of the colon was 
inversely correlated with serum a1PI (r = -0.72, p = 0.0186) and albumin concentrations (r = 
-0.64, p = 0.0470). The compartmental shift (ABR) of epithelial RAGE expression in the ileum 
was strongly associated with the systemic inflammatory biomarker CRP (r = 0.71, p = 0.0465), 
and in the colon was very strongly and inversely correlated with fecal calprotectin concentra-
tions (r = -1.00, p < 0.0001). A direct relationship was observed between epithelial RAGE 
expression in the stomach and serum Spec cPL concentrations (r = 0.90, p = 0.0374). Tissue 
RAGE expression in the gastrointestinal segments evaluated was not correlated with any other 
biomarkers (Table 4). 
 
3.3. Assessment of in vitro binding of RAGE to S100/calgranulin proteins 
Normalized against the non-specific adherence to BSA (negative control, set at 100%), binding 
of 125I-S100A12 protein to recombinant canine RAGE was higher (149%) than that of the 
125I-S100A8/A9 complex (117%) as measured by ELISA (Fig. 5); statistical comparison could 
not be performed due to the experiment size (n = 3). Native PAGE to evaluate canine 
RAGE:S100/calgranulin protein binding revealed multiple large protein bands between approx-
imately 50–150 kDa (not shown), whereby the protein bands appeared more distinct for the 
canine RAGE:S100A8/A9 solutions, suggesting more or stronger canine RAGE:S100A12 than 










Fig. 5 – In vitro binding of the canine S100/calgranu-
lins to canine RAGE assessed by ELISA. Compared to 
BSA as a reference (arbitrarily set to 100%; grey bars), 
more S100A12 protein was bound to recombinant ca-
nine RAGE (149%, left black bar) compared to the 
S100A8/A9 complex (117%, right black bar). Bars: 
means and standard deviations (3 different experi-








This study aimed at evaluating and quantifying the gastrointestinal mucosal expression of 
RAGE in dogs with CIE. This was accomplished by immunofluorescence detection and CLSM- 
guided quantification of RAGE in the apical and basal regions of the epithelial layer in different 
segments of the gastrointestinal tract (i.e., stomach, duodenum, ileum, and colon) in dogs with 
CIE in comparison to healthy control dogs. In contrast to conventional light microscopy, a frac-
tion of tissue specimens is illuminated during CLSM. The standardized procedure of photon 
counting using CLSM and the help of ROI is currently considered as the gold standard method. 
Similar to the results in human studies (Ciccocioppo et al., 2013; Body-Malapel et al., 2019), 
tissue RAGE was expressed along the gastrointestinal tract in both groups of dogs, those af-
fected with CIE and healthy control dogs. This finding suggests gastrointestinal expression of 
RAGE to play a regulatory role in canine health and disease, and the expression levels might 
depend on the presence and spectrum of its ligands. RAGE is constitutively expressed in all 
tissues during embryonic development (Schmidt et al., 2000; Bierhaus et al., 2005), whereas 
postnatal RAGE expression decreases or ceases in most tissues except for a strong expression 
of the receptor in the skin, lungs, and certain cells of the immune system (Oldfield et al., 2001; 
Bierhaus, 2005). RAGE expression increases at sites of inflammation where the receptor is 
primarily localized to inflammatory and epithelial cells (Sparvero et al., 2009). This concept 
warrants consideration for interpreting RAGE expression in the gastrointestinal tract because 
gastrointestinal mucosal immunity is a delicate balance between immune responses and immu-
notolerance. Resulting from RAGE interaction with its ligands, proinflammatory responses are 
produced that also promote oxidative stress (Teissier et al., 2019), and RAGE blockade can 
protect against such conditions, including inflammaging (Teissier et al., 2019). 
Gastric expression of RAGE was generally higher in healthy dogs than in dogs with CIE, 
whereas an opposite trend was seen in the ileum. Significantly higher tissue RAGE expression 






pathways in canine CIE, but the biological relevance of these results warrants further findings 
are mostly consistent with studies in humans with IBD, where tissue RAGE was consistently 
upregulated (Cioccociopo et al. 2013, Body-Malapel 2019). However, in one study, the major-
ity of RAGE positivity was localized to the peri-ulcerative areas of the epithelium (Ciccocioppo 
et al., 2013), which is not a characteristic feature in canine CIE (Washabau et al., 2010, Slovak 
et al., 2015). Crohn’s disease (CD) and ulcerative colitis (UC), the most common forms of IBD 
in humans, are characterized by predominantly granulomatous inflammation (Jumani et al., 
2020), which might explain species differences in RAGE expression because the inflammatory 
infiltrate in dogs is predominantly lymphoplasmacytic (Day et al., 2008). Differences in loca-
tion and mucosal penetration of the disease (Ortigosa, 2005; Body-Malapel et al., 2019; Jumani 
et al., 2020) might also contribute to the differences seen. In contrast to our results, RAGE 
expression is generally poor in the small intestine and colon in healthy humans and mice (Body-
Malapel et al. 2019). This could be a species-specific difference, but the use of different tech-
niques might also explain the discrepancy. As opposed to traditional semi-quantitative immu-
nofluorescence analyses in the previous study (Body-Malapel et al. 2019), quantitative CLSM 
was used in our study and is a more sensitive technique. Quantification of mRNA expression 
could help to verify these findings. 
RAGE expression in the apical and basal regions of the gastrointestinal epithelium was highly 
correlated along the gastrointestinal tract in dogs with CIE, but not in the control group of 
healthy dogs. This result is consistent with those in human IBD patients, pointing to a discon-
tinuous expression of RAGE with low concentrations in non-inflamed gastrointestinal portions 
to reaching maximum levels in inflamed segments where RAGE ligands accumulate Cicco-
cioppo et al., 2013). A trend for an apical-to-basal shift in the expression of epithelial RAGE 
(expressed as ABR) was seen in the duodenum, ileum, and colon of dogs with CIE compared 
to healthy dogs. This finding might point to an attempt to decrease the activation of gastroin-
testinal epithelial transmembrane RAGE associated with the presence or accumulation of lu-
minal stimuli (e.g., PAMPs) or even protect the apical portion of the epithelium from such 
antigens in the face of chronic inflammation. Whether the differences observed between health 
and disease in dogs are linked to the accumulation of RAGE ligands and the impact on func-
tionality (e.g., the possibility of perpetuated proinflammatory signaling induced by RAGE lig-
ands) warrant further study. Differences in tissue RAGE expression between the stomach and 
intestines could reflect differences between gastric and intestinal mucosa in dogs with CIE (Al-
lenspach et al., 2018). However, the possibility of an effect of antisecretory treatment (e.g., 
proton pump inhibitors) or supplements (e.g., probiotics) on RAGE expression cannot be de-
finitively excluded in dogs with CIE. 
The positive relationship of the (primarily apical epithelial) duodenal RAGE expression and 
serum sRAGE concentrations (reflecting a splice-variant or de-anchoring of transmembrane 
[full-length] RAGE) in dogs with CIE further supports a dysregulation or compensatory regu-
lation in the sRAGE/RAGE axis in canine CIE. Provision of increased anti-inflammatory lig-
and-capturing capacity to abrogate proinflammatory transmembrane RAGE signaling (Taguchi 
et al., 2000; Maillard-Lefebvre et al., 2009) might explain the (unexpected) parallel trends in 
circulating decoy receptor (serum sRAGE) levels and small intestinal tissue RAGE expression. 






expression. The sRAGE/RAGE axis derangements in canine CIE appear only partially to de-
pend on histologic lesions because primarily duodenal (but not ileal and to some extent colonic) 
epithelial RAGE expression was linked to the severity of histologic changes. Opposite trends 
in the correlation of tissue RAGE expression and histologic architectural duodenal lesions, 
compared to duodenal inflammatory lesions, are an interesting finding. This is in line with our 
previous observation of serum sRAGE concentrations to inversely correlate with the severity 
of proximal intestinal microscopic lesions (Cabrera-García et al., 2020) and further suggests 
that perturbations in the RAGE axis depend on the type, severity, and/or chronicity of histologic 
lesions. However, careful interpretation of these correlations is needed as cause-and-effect re-
lationships cannot be definitively determined through the results of this study. Also, tissue 
RAGE expression was evaluated only in the epithelial layer and in some segments of the gas-
trointestinal tract in the dogs included in this study. Thus, a contribution of gastrointestinal 
segments not evaluated due to being outside reach of the endoscope, or extra-intestinal organs 
(e.g., exocrine pancreas with concurrent pancreatitis), or even a combination of these to the 
serum sRAGE concentrations cannot be excluded or evaluated. Further, lamina propria infil-
trating or resident cells (e.g., macrophages) could also contribute to gastrointestinal tissue ex-
pression of RAGE (Ciccocioppo et al., 2013), but this warrants further study. 
Gastrointestinal epithelial RAGE expression was not linked to the clinical disease severity (as 
determined by CCECAI score) in dogs with CIE in this study, although very high CCECAI 
scores (Allenspach et al., 2007) and also persistent sRAGE deficiency (Heilmann et al., 2014) 
were associated with poor outcomes. This agrees with the results in a human study on IBD, 
where no correlation was seen between RAGE expression and the severity of clinical signs 
(Ciccocioppo et al., 2013) but contrasts with pulmonary disease studies in humans showing the 
downregulation of RAGE to be an indicator of poor prognosis (Bierhaus et al., 2005). Large 
intestinal mucosal expression of RAGE was negatively associated with albumin and a1PI (but 
not total calcium) concentrations in serum and suggests upregulated epithelial RAGE expres-
sion with hypoalbuminemia (e.g., due to protein-losing enteropathy), which is a negative prog-
nostic factor in canine CIE (Allenspach et al., 2007). This result is consistent with the lack of a 
link between tissue RAGE expression and CCECAI scores because hypoalbuminemia is one of 
the nine criteria included in the CCECAI scoring system. Hypocalcemia is also a negative prog-
nostic factor in canine CIE (Craven et al., 2004; Titmarsh et al., 2015). Associated with hypo-
vitaminosis D, hypocalcemia can contribute to intestinal inflammation (Titmarsh et al., 2015b; 
Allenspach, 2017). Hypovitaminosis D and calcitriol treatment also, directly and indirectly, 
affect the sRAGE/RAGE axis in people (Sung et al., 2013; Lee et al., 2014; Torino et al., 2017), 
but this relationship requires further study in dogs with CIE. 
Except for the apical-to-basal shift in the ileum, gastric or intestinal mucosal expression of 
RAGE was not associated with serum CRP concentrations in dogs with CIE. It was also not 
correlated with any other serum or fecal biomarkers of gastrointestinal inflammation, except 
for fecal calprotectin concentrations. Once again, this finding would indicate a role of tissue 
RAGE (i.e., RAGE upregulation) and the sRAGE/RAGE axis in the inflammatory process in 
canine CIE. Except for these few correlations between tissue RAGE expression and serum or 






serum sRAGE concentrations are also not associated with serum cobalamin or folate concen-
trations, nor with serum calprotectin, S100A12, fecal 1PI, or S100A12 concentrations (Cabrera-
García et al., 2020). The lack of such associations between biomarker levels and the expression 
of RAGE might point to spatial and/or temporal differences in their expression and is also con-
sistent with RAGE (transmembrane and decoy receptor) presenting a non-specific multi-ligand 
receptor as has been demonstrated in human studies (Schmidt et al., 2001; Bierhaus et al., 2005; 
Heilmann and Allenspach, 2017; Teissier et al., 2019). 
We attempted to compare tissue RAGE expression between dogs with FRE and SRE/IRE dogs, 
which generally have higher CCECAI scores (Allenspach et al., 2007; Volkmann et al., 2017). 
However, complete follow-up information was only available for 3 dogs (2 dogs diagnosed 
with FRE and 1 dog with SRE/IRE). In the dog with SRE/IRE, tissue RAGE expression com-
pared to the FRE dogs was higher in the apical compartment (SRE/IRE: AECn= 8.68; FRE: 
AECn = 6.72) but lower in the basal compartment of the colon (SRE/IRE: BECn = 6.49; FRE: 
BECn = 10.13). A basal-to-apical shift in colonic RAGE expression was seen in the dog with 
SRE/IRE (ARB = 1.34) but an apical-to-basal shift with FRE (ARB = 0.66). Statistical com-
parisons were not possible given the small number of dogs in the two subgroups. 
The results of this study provide a basis for further elucidating the immune mechanisms and 
the role of PRRs in the pathogenesis of canine CIE. The standard treatment for human IBD and 
also canine SRE/IRE is based on corticosteroids and/or other immunosuppressive drugs (e.g., 
azathioprine, cyclosporine) with the risk of severe adverse effects, especially with prolonged 
administration (Sulz et al., 2020; Dandrieux, 2016; Erdmann and Heilmann, 2017). Further 
study of the pathways involved in chronic intestinal inflammation (canine CIE and human IBD) 
might lead to novel treatment strategies. Such a possible role of RAGE has been evaluated in a 
rodent model of IBD by placebo-controlled administration of the RAGE-specific inhibitor N- 
Benzyl-N-cyclohexyl-4-chlorobenzamide (FPS-ZM1), which dampened intestinal inflamma-
tion (Body-Malapel et al., 2019). Further studies into such pathway-based treatment strategies 
could benefit from utilizing canine CIE as a spontaneous model for human IBD. 
The in vitro binding assays in this study suggest binding of the canine S100/calgranulins 
S100A12 protein and S100A8/A9 protein complex) to canine RAGE, indicating that both 
S100A12 and calprotectin (S100A8/A9) are ligands for RAGE. 
We acknowledge that this study has some limitations. First, the time between the preparation 
of the samples (i.e., deparaffinization and immunofluorescence staining) and their evaluation 
by CLSM was between 6–11 months. This delay was inevitable given the time for evaluation 
of tissue specimens by this modality. Another limitation is that, because endoscopic tissue bi-
opsies were used, each tissue sample was of slightly different size, orientation, and overall 
quality (Willard et al., 2008). Particularly endoscopic tissue biopsies from the ileum can be of 
lower quality because endoscopic intubation of the ileum from the colon is difficult in some 
dogs, requiring a smaller number of blind biopsies collected in some cases. Finally, pre-illumi-
nation of the slides due to screening immediately after immunofluorescence staining to evaluate 
the quality of the stained slides prior to CLSM is a limitation of the study. This procedure can 







The results of this study suggest a role of RAGE pathways and the sRAGE/RAGE axis in the 
inflammatory process in dogs with CIE. Our findings largely agree with the results of studies 
in humans and experimental models of IBD (Ciccocioppo et al., 2013; Body-Malapel et al., 
2019), further supporting the hypothesis that transmembrane RAGE expression and intracellu-
lar RAGE signaling are involved in the chronic inflammatory response. RAGE antagonization 
(e.g., abrogation of transmembrane RAGE activation and intracellular signaling by synthetic 
anti-inflammatory receptor decoys) appears to be a reasonable novel therapeutic strategy in 
chronic gastrointestinal inflammation. Further research into such targeted (pathway-specific) 
treatment options in dogs with canine CIE may serve as a good model for human IBD. 
 
Footnotes 
1Triton X-100, Roth, Karlsruhe, Germany 
2Polyclonal sheep anti-canine RAGE antibody, R&D Systems, Minneapolis, MN, USA 
3Polyclonal sheep anti-recombinant canine RAGE, Thermo Fisher Scientific, Dreieich, Germany 
4Rabbit anti-goat IgG, Dianova, Hamburg, Germany 
5Tyramide SuperBoostTM Kit, Thermo Fisher Scientific, Dreieich, Germany 
6Alexa FluorTM 488 nm tyramide reagent, Thermo Fisher Scientific, Dreieich, Germany 
7Hoechst 33342 (Molecular probes, Eugene, OR, USA) 
8Olympus IX71 fluorescence microscope, Olympus, Hamburg, Germany 
9CellSens Dimension software, Olympus, Hamburg, Germany 
10Leica TCS SP8 and LAS-X 3.5.5, Leica Microsystems, Mannheim, Germany 
11HyD, Leica Microsystems, Mannheim, Germany 
12HC PL APO CS2 63×/1.30 Glyc, Leica Microsystems, Mannheim, Germany 
13LAS-X 3.4.2 software, Leica Microsystems, Mannheim, Germany 
14MaxiSorpTM Nunc-ImmunoTM Plates, Thermo Scientific, Rockford, IL, USA 
15Recombinant canine RAGE, R&D Systems, Minneapolis, MN, USA 
16Wallac 1470 WIZARD, Perkin Elmer Life and Analytical Sciences, Wellesley, USA 
17ImperialTM Protein Stain, BioTek®, Thermo Scientific, Rockford, IL, USA 
18Quantity One® software (v4.6.5), Bio-Rad Laboratories, Hercules, CA, USA 
19HiPrepTM Sephacryl® S-100 HR, GE Healthcare, Piscataway, NJ, USA 
20ÄKTA basic, GE Healthcare, Piscataway, NJ, USA 
21JMP® v13.1.0, SAS Institute, Cary, NC, USA 
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4.1 Objective of the study 
The goal of the first part of this study was to evaluate serum sRAGE concentrations in a large 
group of dogs with CIE and to assess the possibility of a relationship of serum sRAGE concen-
trations with the clinical disease activity score (CCECAI), histologic lesion severity, serum C-
reactive protein (CRP) concentrations, and serum and fecal calprotectin, S100A12, and α1PI 
concentrations. We hypothesized that (i) serum sRAGE concentrations are severely decreased 
in dogs with CIE, and (ii) serum sRAGE concentrations correlate with the severity of clinical 
disease, the severity of microscopic lesions, and the concentrations of biomarkers reflecting 
gastrointestinal function, inflammation, or protein loss. 
 
The second part of this study aimed at immunohistologically detecting and quantifying mucosal 
RAGE expression along the different segments of the gastrointestinal tract (i.e., stomach, duo-
denum, ileum, and colon) and assessing the possibility of an association of gastrointestinal 
RAGE expression with the serum sRAGE concentration, clinical disease and histologic lesion 
severity, and biomarkers of gastrointestinal function, inflammation, or protein loss. A second-
ary objective of this second part of the study was to determine the in vitro binding of sRAGE 
to the S100/calgranulin proteins in dogs. We hypothesized that (i) RAGE is overexpressed in 
the gastrointestinal mucosal epithelium in dogs with CIE and (ii) increased gastrointestinal 
RAGE expression correlates with the serum sRAGE concentration and indicators of disease 
severity. We also hypothesized that, in vitro, the S100/calgranulin proteins bind to sRAGE. 
 
The materials & methods and the results of these studies, have been discussed and are published 
in two independent publications. The following discussion summarizes the key points, results, 
and conclusions of both studies. 
 
4.2 Discussion of the results 
This study revealed an overall serum sRAGE deficiency and dysregulations in the gastrointes-
tinal mucosal expression of RAGE in dogs with CIE. In addition, sRAGE:S100/calgranulin 
protein binding was confirmed in dogs. 
Tissue RAGE was expressed along the gastrointestinal tract in dogs with CIE and healthy con-
trol dogs, similar to human and experimental animal studies (CICCOCIOPPO et al. 2013, 






RAGE plays a regulatory role in canine health and disease (SCHMIDT et al. 2000, OLDFIELD 
et al. 2001, BIERHAUS et al. 2005). The expression levels of RAGE in dogs likely depend on 
the presence and spectrum of its ligands because a trend for an apical-to-basal shift in the ex-
pression of epithelial RAGE was seen in the duodenum, ileum, and colon of dogs with CIE, 
and RAGE expression was shown to increase at sites of inflammation in human patients 
(SPARVERO et al. 2009). Protection against inflammatory responses, oxidative stress, and in-
flammaging by RAGE blockade by administering a RAGE-specific inhibitor or RAGE-/- 
(BODY-MALAPEL et al. 2019, TEISSIER et al. 2019) adds to the concept of gastrointestinal 
mucosal immunity presenting a delicate balance between immune responses and immunotoler-
ance. 
Significantly higher tissue RAGE expression was seen in the duodenum and colon of dogs with 
CIE – with the same trend in the ileum but opposite trends in the stomach – and a strong corre-
lation of RAGE expression between the apical and basal regions of the gastrointestinal epithe-
lium. This further suggests a role of RAGE signaling pathways in canine CIE. In contrast to 
human IBD, where RAGE is primarily localized to the peri-ulcerative areas of the epithelium 
(CICCOCIOPPO et al. 2013, BODY-MALAPEL 2019), RAGE positivity was consistently up-
regulated in dogs with CIE. Crohn’s disease (CD) and ulcerative colitis (UC), the most common 
forms of IBD in humans, are characterized by predominantly granulomatous inflammation (JU-
MANI et al. 2020), which might explain the species differences in RAGE expression because 
the inflammatory infiltrate in dogs is predominantly lymphoplasmacytic (DAY et al. 2008). 
Differences in disease location and mucosal penetration (ORTIGOSA 2005, BODY-MALA-
PEL et al. 2019, JUMANI et al. 2020) might also contribute to the differences seen. 
In contrast to this study, RAGE expression is generally very low in the small intestine and colon 
in healthy humans and experimental animals (BODY-MALAPEL et al. 2019), reflecting either 
a species-specific difference or might be explained by the use of different techniques. As op-
posed to traditional semi-quantitative immunofluorescence analyses in the study by BODY-
MALAPEL et al. (2019), quantitative confocal laser scanning microscopy (CLSM) was used 
in this study and is a more sensitive technique. 
Together with the positive relationship between duodenal RAGE expression and serum sRAGE 
concentrations, the decrease in serum sRAGE decoy receptor levels and its correlation with the 
severity of proximal gastrointestinal histologic lesions in dogs with CIE supports a dysregula-
tion in the sRAGE/RAGE axis and transmembrane RAGE signaling (i.e., increased activity of 
the cellular receptor leading to pro-inflammatory intracellular signaling) in canine CIE, either 






ligand-capturing capacity to abrogate proinflammatory transmembrane RAGE signaling 
(TAGUCHI et al. 2000, MAILLARD-LEFEBVRE et al. 2009) is a possible explanation for the 
parallel trends in circulating decoy receptor (serum sRAGE) levels and small intestinal tissue 
RAGE expression. Alternatively, serum sRAGE levels could merely reflect the degree of in-
testinal tissue RAGE expression. Opposite trends in the correlation of tissue RAGE expression 
and histologic architectural duodenal lesions, compared to duodenal inflammatory lesions, are 
in line with the observation of serum sRAGE concentrations to inversely correlate with the 
severity of proximal intestinal microscopic lesions and suggests that perturbations in the RAGE 
axis depend on the type, severity, and/or chronicity of histologic lesions. Endoscopic lesion 
scores were not obtained in this study and could not be evaluated for a possible association with 
serum sRAGE concentrations or gastrointestinal epithelial RAGE expression. 
The severity of clinical signs in dogs with CIE (as determined by CCECAI score) was not 
correlated with serum sRAGE concentrations or the gastrointestinal epithelial expression of 
RAGE, although very high CCECAI scores (ALLENSPACH et al. 2007) and also persistent 
sRAGE deficiency (HEILMANN et al. 2014) were associated with poor outcomes. This finding 
is compatible with a lack of correlation between RAGE positivity and the clinical activity index 
in human patients with IBD (CICCOCIOPPO et al. 2013). Our findings contrast those of an-
other study, showing an inverse association between clinical disease activity and serum sRAGE 
concentrations in Crohn‘s disease and ulcerative colitis patients (CICCOCIOPPO et al. 2015). 
Like this study, CICCOCIOPPO et al. (2013) found no correlation with previous treatment or 
disease length in human patients. Comparison of tissue RAGE expression between dogs with 
FRE and SRE/IRE dogs was attempted. However, complete follow-up information was only 
available for a small number of dogs limiting statistical comparisons between the two sub-
groups. 
The negative association of large intestinal mucosal RAGE expression with serum albumin and 
a1PI (markers of gastrointestinal protein loss) concentrations suggests an upregulated epithelial 
RAGE expression with hypoalbuminemia (e.g., due to protein-losing enteropathy [PLE]), 
which is a negative prognostic factor in canine CIE (ALLENSPACH et al. 2007). This result 
agrees with the lack of a link between tissue RAGE expression and CCECAI scores because 
hypoalbuminemia is one of the nine criteria included in the CCECAI scoring system. Lack of 
an association between serum sRAGE concentrations and any biomarkers of gastrointestinal 
function or inflammation in serum or fecal specimens – despite a trend of an association seen 






in the expression of these molecules and by identifying several different three-dimensional mo-
lecular structures by RAGE. The latter involves exogenous ligands and endogenous molecules 
like the S100/calgranulin proteins (BIERHAUS et al. 2005). Consistent with this study‘s re-
sults, an association of serum sRAGE with concentrations of fecal calprotectin or serum 
S100A12 was also not observed in patients with Crohn‘s disease (CICCOCIOPPO et al. 2015). 
In contrast, there was an inverse relationship between serum sRAGE and fecal calprotectin in 
patients with ulcerative colitis (CICCOCIOPPO et al. 2015). Lack of a correlation between 
serum concentrations of sRAGE and CRP in canine CIE also agrees with the findings in ulcer-
ative colitis patients but differs from findings in patients with Crohn‘s disease (MEIJER et al. 
2014, CICCOCIOPPO et al. 2015). Similarly, gastric or intestinal mucosal expression of RAGE 
was also not associated with serum CRP concentrations or any other serum or fecal biomarkers 
of gastrointestinal inflammation in dogs with CIE, indicating a role of tissue RAGE (i.e., RAGE 
upregulation) and the sRAGE/RAGE axis in the inflammatory process in canine CIE. The lack 
of such associations between biomarker levels and RAGE expression also points to spatial 
and/or temporal differences in their expression. It is also consistent with RAGE (transmem-
brane and decoy receptor) presenting a non-specific multi-ligand receptor (SCHMIDT et al. 
2001, BIERHAUS et al. 2005, HEILMANN and ALLENSPACH 2017, Teissier et al. 2019). 
Therefore, further examination of the ligand-RAGE pathways and the sRAGE/ RAGE axis is 
warranted. Whether genetic defects in the RAGE gene contribute to a disruption in 
sRAGE/RAGE signaling (WANG et al. 2014) in canine CIE is unknown and requires further 
investigation. 
The in vitro binding assays in this study suggest binding of the canine S100/calgranulins 
(S100A12 protein and S100A8/A9 protein complex) to canine RAGE, indicating that both 
S100A12 and calprotectin (S100A8/A9) are ligands for RAGE. 
 
4.3 Limitations of the study 
Some limitations of the study warrant to be acknowledged. The risk of a concurrent disease 
process (e.g., chronic or subclinical pancreatitis) affecting concentrations of serum sRAGE in 
some dogs cannot be entirely excluded. 
Tissue RAGE expression in dogs with CIE was evaluated based on endoscopic tissue biopsies, 
where each tissue sample is of slightly different size, orientation, and overall quality 
(WILLARD et al. 2008). Unlike conventional light microscopy, where whole tissue specimens 
are evaluated, only fractions of such specimens are illuminated during confocal laser scanning 






and the help of ROI is currently considered as the gold standard method for quantitative tissue 
expression analyses. The delay between preparation of the tissue samples (i.e., deparaffiniza-
tion and immunofluorescence staining) and their evaluation by CLSM was between 6–11 
months, which was inevitable given the time for evaluation of tissue specimens by CLSM. Pre-
illumination of the slides due to screening immediately after immunofluorescence staining to 
evaluate the quality of the stained slides prior to CLSM can weaken the signal intensity obtained 
during the CLSM analysis. Infiltrating or resident cells of the lamina propria may contribute to 
gastrointestinal tissue RAGE expression (CICCOCIOPPO et al. 2013), but this warrants further 
study. 
Histopathologic examination of gastrointestinal tissue biopsies was done by 9 separate board-
certified pathologists, with the risk of significant interobserver variability despite using stand-
ardized criteria (JERGENS et al. 2014). Also, some gastrointestinal segments were not assessed 
due to being outside the reach of the endoscope. 
The study of certain protein biomarkers in serum and fecal samples involved a small number 
of dogs. Hence, the possibility of a type II error to find no major variations or correlations 
remains a potential risk. 
 
4.4 Conclusions 
This study confirms that serum sRAGE concentrations are significantly decreased in dogs with 
CIE and correlate with the severity of histologic lesions. The results also suggest a role of 
RAGE pathways and the sRAGE/RAGE axis in the chronic inflammatory responses in dogs 
with CIE. Whether the observed deficiency in systemic concentrations of this decoy receptor is 
a cause (decreased systemic development leading to the pathogenesis of canine CIE) or conse-
quence of CIE (inflammatory consumption) warrants further investigation. This study also 
shows that S100A12 and calprotectin (S100A8/A9 complex) are RAGE ligands. These results 
provide a basis for further elucidating the immune mechanisms and the role of pattern-recogni-
tion receptors (PRRs) in the pathogenesis of canine CIE. Further study of these pathways in 
canine CIE (and human IBD) is expected to bring about novel treatment strategies with poten-
tially less severe adverse effects than traditional immunosuppressive drugs (e.g., corticoster-
oids) (DANDRIEUX 2016, ERDMANN and HEILMANN 2017). Further studies into such 
pathway-based treatment strategies, particularly RAGE antagonization (e.g., abrogation of 
transmembrane RAGE activation and intracellular signaling by synthetic anti-inflammatory re-
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Background: Chronic inflammatory enteropathies (CIE) are an important group of gastroin-
testinal diseases in dogs, and dogs with CIE are subclassified as having either food-responsive 
(FRE) or immunosuppressive-responsive/-refractory enteropathy (IRE). The innate immune 
system has been shown to play a central role in the pathogenesis of CIE  in dogs. Innate immune 
dysregulations in canine CIE involve the signaling of innate immune receptors, such as the 
pattern-recognition receptors (PRRs). The receptor for advanced glycation end products 
(RAGE) is a PRR that has not been investigated extensively in canine CIE. The anti-
inflammatory decoy receptor soluble RAGE (sRAGE) can compete for ligand-binding to 
transmembrane (full-length) RAGE and thus abrogate pro-inflammatory cellular post-receptor 
responses. A previous study in dogs showed that serum soluble RAGE (sRAGE) concentrations 
are decreased in dogs with CIE, leading to the hypothesis that the RAGE/sRAGE axis is 
dysregulated in canine CIE. This hypothesis was further investigated in this study. 
Objectives: This study aimed to determine serum sRAGE concentrations in canine CIE and 
their association with histological and clinicopathological evidence of CIE, including serum 
and fecal biomarkers of gastrointestinal inflammation or protein loss. Also, the expression of 
full-length RAGE along the gastrointestinal tract (stomach, duodenum, ileum, and colon) was 
evaluated in canine CIE using immunofluorescence analysis. Quantitative gastrointestinal epi-
thelial expression of RAGE in dogs with CIE was compared to that in healthy control dogs and 
was evaluated for an association with the serum sRAGE concentration and with clinical, clini-







Material and Methods: Serum and patient data from a total of 102 dogs diagnosed with CIE 
were used in the first part of this study. All dogs underwent a standard diagnostic work-up, 
which included a minimum database (hematology, serum biochemistry, urinalysis, fecal 
examination, gastrointestinal profile, and biomarkers of gastrointestinal inflammation or 
protein loss), further diagnostics to exclude other gastrointestinal and extra-gastrointestinal 
disorders that can mimic CIE (e.g., serum baseline cortisol), abdominal diagnostic imaging, 
histopathological evaluation to document inflammation, and sequential treatment trials. Dogs 
that showed a complete clinical response to an elimination diet (novel or hydrolyzed protein 
diet) were classified as FRE; those that required anti-inflammatory/immunosuppressive treat-
ment (prednisolone, cyclosporine) were diagnosed as IRE. Gastrointestinal tissue biopsies from 
15 dogs with CIE and 9 healthy dogs were subjected to RAGE immunofluorescence detection 
and quantification by laser-scanning microscopy. Statistical analyses included non-parametric 
two- or multiple group comparison tests and correlation coefficients (Spearman r) with 
multiple-comparison corrections if needed. Statistical significance was set at P < 0.05. 
Results: Serum sRAGE concentrations were not correlated with biomarkers of gastrointestinal 
function (cobalamin, folate), inflammation (C-reactive protein, calprotectin, S100A12), or pro-
tein loss (a1-proteinase inhibitor, albumin). However, serum soluble RAGE decreases were 
linked to more severe microscopic lesions in the proximal small intestine. 
RAGE positivity was detected in all biopsies from dogs with CIE and healthy controls. Duode-
nal and colonic epithelial RAGE expression was significantly higher in dogs with CIE than in 
healthy dogs. RAGE expression in dogs with CIE was also higher in the ileum but lower in the 
stomach, though both differences did not reach statistical significance. Gastrointestinal 
epithelial RAGE expression was not correlated with the age or body weight of the dogs, the 
duration of gastrointestinal clinical signs, or the clinical disease activity (CCECAI) score. 
Histologic gastrointestinal lesions and biomarkers of gastrointestinal inflammation were related 
to segmental RAGE expression. In dogs with CIE, soluble RAGE receptor concentrations in 
serum were correlated with the apical epithelial expression of RAGE in the duodenum. 
Conclusions: This study showed a dysregulation of epithelial RAGE expression along the 
gastrointestinal tract and the RAGE/sRAGE axis in canine CIE. These findings suggest that 
RAGE signaling plays a role in the pathogenesis of canine CIE. However, gastrointestinal 
overexpression of RAGE was seen with less severe disease and was also paralleled by higher 
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Einleitung: Zu den chronisch-entzündlichen Enteropathien (chronic inflammatory enteropa-
thies, CIE) beim Hund zählen vor allem zwei Erkrankungsformen, die Futtermittel-responsive 
Enteropathie (FRE) und die Immunsuppressiva-responsive (bzw. -refraktäre) Enteropathie 
(IRE). Mehrere Studien deuten darauf, dass der angeborenen Immunität eine zentrale Rolle bei 
der Pathogenese der CIE des Hundes zukommt. Dysregulationen im angeborenen Immunsys-
tem bei Hunden mit CIE schließen die Signalwege bestimmter Rezeptoren ein, wie die Muster-
erkennungsrezeptoren (pattern recognition receptors, PRRs). Der Rezeptor für fortgeschrittene 
Glykierungsendprodukte (receptor for advanced glycation end products, RAGE) zählt zu den 
PRRs. Die lösliche, nicht membranständige RAGE-Form (soluble RAGE, sRAGE) ist eine an-
tiinflammatorisch wirksame Rezeptorattrappe (decoy receptor), die um Ligandenbindung des 
Transmembranrezeptors (full-length RAGE) konkurriert und proinflammatorische zelluläre Po-
strezeptorsignale aufhebt oder abschwächt. Serum sRAGE-Konzentrationen zeigten sich bei 
Hunden mit CIE deutlich vermindert, was zu der Hypothese führt, dass Fehlregulationen in der 
RAGE/sRAGE-Achse bei Hunden mit CIE eine pathogenetische Rolle spielen. 
Ziele der Untersuchungen: Ziel dieser Studie ist die Bestimmung der Serum-sRAGE-Kon-
zentrationen bei Hunden mit CIE und deren Zusammenhang mit histologischen sowie klinisch-
pathologischen Befunden. Ein weiteres Ziel der Studie ist der quantitative Vergleich der Ex-
pression von Transmembran (full-length)-RAGE entlang des Gastrointestinaltrakts bei Hunden 
mit CIE sowie die Untersuchung auf deren Zusammenhang mit Serum-sRAGE-Konzentratio-






Material und Methoden: Im ersten Teil der Studie wurden 102 mit CIE diagnostizierte Hunde 
eingeschlossen. Alle Hunde durchliefen eine standardisierte Diagnostik (Hämatologie, Serum-
chemie, Urinanalyse, Kotuntersuchung, Gastrointestinalprofil und Biomarker für gastrointesti-
nale Entzündung bzw. Proteinverlust) sowie weitere Diagnostik zum Ausschluss anderer gast-
rointestinaler sowie extra-gastrointestinaler Erkrankungen. Weiter erfolgte bei einigen Hunden 
eine bildgebende Diagnostik des Abdomens und die pathohistologische Beurteilung von gast-
rointestinalen Gewebeproben. Anhand des Therapieerfolgs wurden Hunde, die nach Eliminati-
onsdiät (neuartige Proteinquelle oder Proteinhydrolysat) eine vollständige klinische Remission 
erfuhren, als FRE klassifiziert. Hunde, die einer entzündungshemmenden bzw. immunsuppres-
siven Therapie mit Prednisolon und/oder Cyclosporin bedurften, wurden als IRE diagnostiziert. 
Gewebebiopsien des Gastrointestinaltrakts von 12 Hunden mit CIE und 9 gesunden Kontroll-
hunden wurden der Immunfluoreszenzfärbung zum Nachweis von RAGE sowie dessen Quan-
tifizierung durch konfokale Laserscanmikroskopie unterzogen. Die statistischen Auswertungen 
umfassten nichtparametrische Zwei- oder Mehrfachgruppen-Vergleichstests und Korrelations-
koeffizienten (Spearman r). Die statistische Signifikanz wurde mit P < 0,05 festgelegt. 
Ergebnisse: Die sRAGE-Konzentrationen der 102 Hunde mit CIE korrelierten nicht mit Bio-
markern für eine gestörte gastrointestinale Funktion, Entzündung oder Proteinverlust. Ernied-
rigte sRAGE-Konzentrationen waren mit hochgradigen histologischen Veränderungen im pro-
ximalen Dünndarm verbunden. In allen Gewebebiopsien des Gastrointestinaltraktes von Hun-
den mit CIE sowie gesunden Kontrolltieren war ein positiver Immunfluoreszenznachweis von 
RAGE festzustellen. Die Gewebe-Expression von RAGE im Duodenum und Kolon war bei 
CIE Hunden signifikant höher als bei gesunden Tieren. Im Ileum war RAGE bei kranken Hun-
den ebenfalls stärker, im Magen dagegen geringer, exprimiert als bei gesunden Hunden – je-
doch erreichten diese Unterschiede keine statistische Signifikanz. Die gastrointestinale RAGE-
Expression korrelierte nicht mit dem Alter oder Körpergewicht der Hunde, der Dauer gastroin-
testinaler Symptome oder dem klinischen CCECAI-Score. Einzelne histologische Läsionen im 
Magen-Darm-Trakt sowie Veränderungen in gastrointestinalen Entzündungsmarkers korrelier-
ten mit der segmentalen RAGE-Expression. Lösliche RAGE-Rezeptorkonzentrationen im Se-
rum korrelierten bei Hunden mit CIE mit der apikalen RAGE-Expression im Duodenum. 
Schlussfolgerungen: Die Ergebnisse deuten auf eine Dysregulation der RAGE/sRAGE-Achse 
bei der CIE des Hundes und legen nahe, dass die RAGE-Signalwege eine Rolle bei der Patho-
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